0001160420 2026-01-01 2026-06-30 0001160420 2026-08-13 0001160420 2026-06-30 0001160420 2025-12-31 0001160420 ADIA:BiologicsMember 2026-06-30 0001160420 ADIA:BiologicsMember 2025-12-31 0001160420 ADIA:Special2022SeriesAPreferredStockMember 2026-06-30 0001160420 ADIA:Special2022SeriesAPreferredStockMember 2025-12-31 0001160420 us-gaap:SeriesAPreferredStockMember 2026-06-30 0001160420 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001160420 us-gaap:SeriesCPreferredStockMember 2026-06-30 0001160420 us-gaap:SeriesCPreferredStockMember 2025-12-31 0001160420 us-gaap:CommonClassAMember 2026-06-30 0001160420 us-gaap:CommonClassAMember 2025-12-31 0001160420 us-gaap:CommonClassBMember 2026-06-30 0001160420 us-gaap:CommonClassBMember 2025-12-31 0001160420 2026-04-01 2026-06-30 0001160420 2025-04-01 2025-06-30 0001160420 2025-01-01 2025-06-30 0001160420 ADIA:SalesOfSupplementsMember 2026-04-01 2026-06-30 0001160420 ADIA:SalesOfSupplementsMember 2025-04-01 2025-06-30 0001160420 ADIA:SalesOfSupplementsMember 2026-01-01 2026-06-30 0001160420 ADIA:SalesOfSupplementsMember 2025-01-01 2025-06-30 0001160420 ADIA:MedicalProceduresMember 2026-04-01 2026-06-30 0001160420 ADIA:MedicalProceduresMember 2025-04-01 2025-06-30 0001160420 ADIA:MedicalProceduresMember 2026-01-01 2026-06-30 0001160420 ADIA:MedicalProceduresMember 2025-01-01 2025-06-30 0001160420 ADIA:SalesOfBiologicsMember 2026-04-01 2026-06-30 0001160420 ADIA:SalesOfBiologicsMember 2025-04-01 2025-06-30 0001160420 ADIA:SalesOfBiologicsMember 2026-01-01 2026-06-30 0001160420 ADIA:SalesOfBiologicsMember 2025-01-01 2025-06-30 0001160420 ADIA:ServicesMember 2026-04-01 2026-06-30 0001160420 ADIA:ServicesMember 2025-04-01 2025-06-30 0001160420 ADIA:ServicesMember 2026-01-01 2026-06-30 0001160420 ADIA:ServicesMember 2025-01-01 2025-06-30 0001160420 ADIA:ShippingAndDeliveryMember 2026-04-01 2026-06-30 0001160420 ADIA:ShippingAndDeliveryMember 2025-04-01 2025-06-30 0001160420 ADIA:ShippingAndDeliveryMember 2026-01-01 2026-06-30 0001160420 ADIA:ShippingAndDeliveryMember 2025-01-01 2025-06-30 0001160420 ADIA:SupplementsMember 2026-04-01 2026-06-30 0001160420 ADIA:SupplementsMember 2025-04-01 2025-06-30 0001160420 ADIA:SupplementsMember 2026-01-01 2026-06-30 0001160420 ADIA:SupplementsMember 2025-01-01 2025-06-30 0001160420 ADIA:ProceduresMember 2026-04-01 2026-06-30 0001160420 ADIA:ProceduresMember 2025-04-01 2025-06-30 0001160420 ADIA:ProceduresMember 2026-01-01 2026-06-30 0001160420 ADIA:ProceduresMember 2025-01-01 2025-06-30 0001160420 ADIA:BiologicsMember 2026-04-01 2026-06-30 0001160420 ADIA:BiologicsMember 2025-04-01 2025-06-30 0001160420 ADIA:BiologicsMember 2026-01-01 2026-06-30 0001160420 ADIA:BiologicsMember 2025-01-01 2025-06-30 0001160420 ADIA:Special2022SeriesAPreferredMember 2024-12-31 0001160420 ADIA:SeriesAPreferredMember 2024-12-31 0001160420 ADIA:SeriesCPreferredMember 2024-12-31 0001160420 ADIA:SharesToBeIssuedMember 2024-12-31 0001160420 ADIA:Special2022SeriesAPreferredMember 2025-03-31 0001160420 ADIA:SeriesAPreferredMember 2025-03-31 0001160420 ADIA:SeriesCPreferredMember 2025-03-31 0001160420 ADIA:SharesToBeIssuedMember 2025-03-31 0001160420 ADIA:ClassACommonStockMember 2024-12-31 0001160420 ADIA:ClassBCommonStockMember 2024-12-31 0001160420 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001160420 us-gaap:RetainedEarningsMember 2024-12-31 0001160420 2024-12-31 0001160420 ADIA:ClassACommonStockMember 2025-03-31 0001160420 ADIA:ClassBCommonStockMember 2025-03-31 0001160420 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001160420 us-gaap:RetainedEarningsMember 2025-03-31 0001160420 2025-03-31 0001160420 ADIA:Special2022SeriesAPreferredMember 2025-12-31 0001160420 ADIA:SeriesAPreferredMember 2025-12-31 0001160420 ADIA:SeriesCPreferredMember 2025-12-31 0001160420 ADIA:SharesToBeIssuedMember 2025-12-31 0001160420 ADIA:Special2022SeriesAPreferredMember 2026-03-31 0001160420 ADIA:SeriesAPreferredMember 2026-03-31 0001160420 ADIA:SeriesCPreferredMember 2026-03-31 0001160420 ADIA:SharesToBeIssuedMember 2026-03-31 0001160420 ADIA:ClassACommonStockMember 2025-12-31 0001160420 ADIA:ClassBCommonStockMember 2025-12-31 0001160420 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001160420 us-gaap:RetainedEarningsMember 2025-12-31 0001160420 ADIA:ClassACommonStockMember 2026-03-31 0001160420 ADIA:ClassBCommonStockMember 2026-03-31 0001160420 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001160420 us-gaap:RetainedEarningsMember 2026-03-31 0001160420 2026-03-31 0001160420 ADIA:Special2022SeriesAPreferredMember 2025-01-01 2025-03-31 0001160420 ADIA:SeriesAPreferredMember 2025-01-01 2025-03-31 0001160420 ADIA:SeriesCPreferredMember 2025-01-01 2025-03-31 0001160420 ADIA:SharesToBeIssuedMember 2025-01-01 2025-03-31 0001160420 ADIA:Special2022SeriesAPreferredMember 2025-04-01 2025-06-30 0001160420 ADIA:SeriesAPreferredMember 2025-04-01 2025-06-30 0001160420 ADIA:SeriesCPreferredMember 2025-04-01 2025-06-30 0001160420 ADIA:SharesToBeIssuedMember 2025-04-01 2025-06-30 0001160420 ADIA:ClassACommonStockMember 2025-01-01 2025-03-31 0001160420 ADIA:ClassBCommonStockMember 2025-01-01 2025-03-31 0001160420 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001160420 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001160420 2025-01-01 2025-03-31 0001160420 ADIA:ClassACommonStockMember 2025-04-01 2025-06-30 0001160420 ADIA:ClassBCommonStockMember 2025-04-01 2025-06-30 0001160420 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001160420 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001160420 ADIA:Special2022SeriesAPreferredMember 2026-01-01 2026-03-31 0001160420 ADIA:SeriesAPreferredMember 2026-01-01 2026-03-31 0001160420 ADIA:SeriesCPreferredMember 2026-01-01 2026-03-31 0001160420 ADIA:SharesToBeIssuedMember 2026-01-01 2026-03-31 0001160420 ADIA:Special2022SeriesAPreferredMember 2026-04-01 2026-06-30 0001160420 ADIA:SeriesAPreferredMember 2026-04-01 2026-06-30 0001160420 ADIA:SeriesCPreferredMember 2026-04-01 2026-06-30 0001160420 ADIA:SharesToBeIssuedMember 2026-04-01 2026-06-30 0001160420 ADIA:ClassACommonStockMember 2026-01-01 2026-03-31 0001160420 ADIA:ClassBCommonStockMember 2026-01-01 2026-03-31 0001160420 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001160420 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001160420 2026-01-01 2026-03-31 0001160420 ADIA:ClassACommonStockMember 2026-04-01 2026-06-30 0001160420 ADIA:ClassBCommonStockMember 2026-04-01 2026-06-30 0001160420 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001160420 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001160420 ADIA:Special2022SeriesAPreferredMember 2025-06-30 0001160420 ADIA:SeriesAPreferredMember 2025-06-30 0001160420 ADIA:SeriesCPreferredMember 2025-06-30 0001160420 ADIA:SharesToBeIssuedMember 2025-06-30 0001160420 ADIA:ClassACommonStockMember 2025-06-30 0001160420 ADIA:ClassBCommonStockMember 2025-06-30 0001160420 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001160420 us-gaap:RetainedEarningsMember 2025-06-30 0001160420 2025-06-30 0001160420 ADIA:Special2022SeriesAPreferredMember 2026-06-30 0001160420 ADIA:SeriesAPreferredMember 2026-06-30 0001160420 ADIA:SeriesCPreferredMember 2026-06-30 0001160420 ADIA:SharesToBeIssuedMember 2026-06-30 0001160420 ADIA:ClassACommonStockMember 2026-06-30 0001160420 ADIA:ClassBCommonStockMember 2026-06-30 0001160420 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001160420 us-gaap:RetainedEarningsMember 2026-06-30 0001160420 us-gaap:SeriesAPreferredStockMember 2022-06-16 2022-06-17 0001160420 ADIA:MonicaSherMember ADIA:SharesToBeIssuedMember us-gaap:SeriesCPreferredStockMember 2024-08-18 2024-08-19 0001160420 ADIA:RichardEdwardsMember ADIA:SharesToBeIssuedMember us-gaap:SeriesCPreferredStockMember 2024-09-09 2024-09-10 0001160420 ADIA:KalpeshBarotMember ADIA:SharesToBeIssuedMember us-gaap:SeriesCPreferredStockMember 2024-09-22 2024-09-23 0001160420 ADIA:EvanThomasMember ADIA:SharesToBeIssuedMember us-gaap:SeriesCPreferredStockMember 2025-10-12 2025-10-13 0001160420 ADIA:CementFactoryLLCMember 2026-01-01 2026-06-30 0001160420 srt:MinimumMember 2026-06-30 0001160420 srt:MaximumMember 2026-06-30 0001160420 ADIA:SalesOfSupplementsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2026-01-01 2026-06-30 0001160420 ADIA:SalesOfSupplementsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2025-01-01 2025-06-30 0001160420 ADIA:MedicalProceduresMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2026-01-01 2026-06-30 0001160420 ADIA:MedicalProceduresMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2025-01-01 2025-06-30 0001160420 ADIA:SalesOfBiologicsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2026-01-01 2026-06-30 0001160420 ADIA:SalesOfBiologicsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2025-01-01 2025-06-30 0001160420 ADIA:ServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2026-01-01 2026-06-30 0001160420 ADIA:ServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2025-01-01 2025-06-30 0001160420 ADIA:ShippingAndDeliveryMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2026-01-01 2026-06-30 0001160420 ADIA:ShippingAndDeliveryMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2025-01-01 2025-06-30 0001160420 ADIA:TotalRevenueMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2026-01-01 2026-06-30 0001160420 ADIA:TotalRevenueMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2025-01-01 2025-06-30 0001160420 ADIA:CostOfSupplementsMember 2026-01-01 2026-06-30 0001160420 ADIA:CostOfSupplementsMember ADIA:CostOfRevenueMember us-gaap:ProductConcentrationRiskMember 2026-01-01 2026-06-30 0001160420 ADIA:CostOfSupplementsMember 2025-01-01 2025-06-30 0001160420 ADIA:CostOfSupplementsMember ADIA:CostOfRevenueMember us-gaap:ProductConcentrationRiskMember 2025-01-01 2025-06-30 0001160420 ADIA:CostForAdministrationOfMedicalProceduresMember 2026-01-01 2026-06-30 0001160420 ADIA:CostForAdministrationOfMedicalProceduresMember ADIA:CostOfRevenueMember us-gaap:ProductConcentrationRiskMember 2026-01-01 2026-06-30 0001160420 ADIA:CostForAdministrationOfMedicalProceduresMember 2025-01-01 2025-06-30 0001160420 ADIA:CostForAdministrationOfMedicalProceduresMember ADIA:CostOfRevenueMember us-gaap:ProductConcentrationRiskMember 2025-01-01 2025-06-30 0001160420 ADIA:CostOfBiologicsMember 2026-01-01 2026-06-30 0001160420 ADIA:CostOfBiologicsMember ADIA:CostOfRevenueMember us-gaap:ProductConcentrationRiskMember 2026-01-01 2026-06-30 0001160420 ADIA:CostOfBiologicsMember 2025-01-01 2025-06-30 0001160420 ADIA:CostOfBiologicsMember ADIA:CostOfRevenueMember us-gaap:ProductConcentrationRiskMember 2025-01-01 2025-06-30 0001160420 ADIA:TotalCostOfRevenueMember ADIA:CostOfRevenueMember us-gaap:ProductConcentrationRiskMember 2026-01-01 2026-06-30 0001160420 ADIA:TotalCostOfRevenueMember ADIA:CostOfRevenueMember us-gaap:ProductConcentrationRiskMember 2025-01-01 2025-06-30 0001160420 2026-04-01 2026-06-03 0001160420 ADIA:BiologicProductsMember 2026-06-30 0001160420 ADIA:BiologicProductsMember 2025-12-31 0001160420 us-gaap:FurnitureAndFixturesMember 2026-06-30 0001160420 us-gaap:FurnitureAndFixturesMember 2025-12-31 0001160420 us-gaap:MachineryAndEquipmentMember 2026-06-30 0001160420 us-gaap:MachineryAndEquipmentMember 2025-12-31 0001160420 ADIA:BioleteMember 2024-07-11 0001160420 ADIA:BioleteLLCMember 2024-07-10 2024-07-11 0001160420 ADIA:BioleteLLCMember 2024-07-11 0001160420 ADIA:BioleteMember 2025-09-30 0001160420 ADIA:CementFactoryMember ADIA:BioleteInventoryMember 2025-09-30 0001160420 ADIA:CementFactoryMember ADIA:BioleteTrademarksMember 2025-09-30 0001160420 ADIA:CementFactoryMember ADIA:BioleteWebsiteMember 2025-09-30 0001160420 ADIA:CementFactoryMember 2025-09-30 0001160420 ADIA:CementFactoryMember 2026-01-01 2026-06-30 0001160420 ADIA:CementFactoryMember 2025-01-01 2025-12-31 0001160420 ADIA:CementFactoryMember 2026-06-30 0001160420 ADIA:CementFactoryMember 2025-12-31 0001160420 ADIA:CementFactoryNutritionMember us-gaap:SeriesCPreferredStockMember 2024-07-28 2024-07-29 0001160420 ADIA:CementFactoryLLCMember 2024-09-24 0001160420 ADIA:CementFactoryLLCMember 2024-09-28 2024-09-29 0001160420 srt:ChiefExecutiveOfficerMember 2026-06-30 0001160420 srt:ChiefExecutiveOfficerMember 2026-01-01 2026-06-30 0001160420 srt:ChiefExecutiveOfficerMember 2025-01-01 2025-12-31 0001160420 srt:ChiefExecutiveOfficerMember 2025-12-31 0001160420 srt:ChiefExecutiveOfficerMember ADIA:CEOCreditLineMember 2026-04-01 2026-06-30 0001160420 srt:ChiefExecutiveOfficerMember ADIA:CEOCreditLineMember 2025-04-01 2025-06-30 0001160420 srt:ChiefExecutiveOfficerMember ADIA:CEOCreditLineMember 2026-01-01 2026-06-30 0001160420 srt:ChiefExecutiveOfficerMember ADIA:CEOCreditLineMember 2025-01-01 2025-06-30 0001160420 srt:ChiefExecutiveOfficerMember ADIA:CEOCreditLineMember 2026-06-30 0001160420 srt:ChiefExecutiveOfficerMember ADIA:CEOCreditLineMember 2025-12-31 0001160420 ADIA:AspireRegenerativeTherapyMember 2025-07-15 0001160420 ADIA:AspireRegenerativeTherapyMember 2025-12-31 0001160420 ADIA:AspireRegenerativeTherapyMember 2025-06-30 0001160420 ADIA:AspireRegenerativeTherapyMember 2026-04-01 2026-06-30 0001160420 ADIA:AspireRegenerativeTherapyMember 2025-04-01 2025-06-30 0001160420 ADIA:AspireRegenerativeTherapyMember 2026-01-01 2026-06-30 0001160420 ADIA:AspireRegenerativeTherapyMember 2025-01-01 2025-06-30 0001160420 ADIA:GAIPMember 2026-04-06 0001160420 ADIA:GAIPMember 2026-04-01 2026-06-30 0001160420 ADIA:GAIPMember 2026-01-01 2026-06-30 0001160420 ADIA:GAIPMember 2026-06-30 0001160420 2025-01-01 2025-12-31 0001160420 us-gaap:CommonStockMember 2026-06-30 0001160420 us-gaap:CommonClassAMember 2026-06-30 0001160420 us-gaap:CommonClassBMember 2026-06-30 0001160420 ADIA:RegulationAFilingMember 2024-07-08 2024-07-09 0001160420 us-gaap:CommonStockMember 2025-05-04 2025-05-05 0001160420 ADIA:RegulationAFilingMember 2025-06-05 2025-06-06 0001160420 ADIA:RegulationAFilingMember 2025-06-10 2025-06-11 0001160420 us-gaap:CommonClassAMember 2025-12-31 0001160420 us-gaap:CommonClassBMember 2025-12-31 0001160420 us-gaap:PreferredStockMember 2026-06-30 0001160420 ADIA:Special2022SeriesAPreferredStockMember 2026-06-30 0001160420 us-gaap:SeriesAPreferredStockMember 2025-05-04 2025-05-05 0001160420 us-gaap:SeriesAPreferredStockMember 2025-05-05 0001160420 ADIA:TwoOfficersMember us-gaap:SeriesCPreferredStockMember 2025-01-01 2025-12-31 0001160420 ADIA:Special2022SeriesAPreferredStockMember 2025-12-31 0001160420 ADIA:AdiaMedAssetsMember 2026-06-30 0001160420 ADIA:AdiaMedAssetsMember 2025-12-31 0001160420 ADIA:AdiaLabsAssetsMember 2026-06-30 0001160420 ADIA:AdiaLabsAssetsMember 2025-12-31 0001160420 ADIA:UnallocatedCorporateAssetsMember 2026-06-30 0001160420 ADIA:UnallocatedCorporateAssetsMember 2025-12-31 0001160420 us-gaap:CorporateMember 2026-01-01 2026-06-30 0001160420 ADIA:BioleteMember 2026-01-01 2026-06-30 0001160420 ADIA:AdiaMedMember 2026-01-01 2026-06-30 0001160420 ADIA:AdiaLabsMember 2026-01-01 2026-06-30 0001160420 ADIA:MedicalProceduresMember us-gaap:CorporateMember 2026-01-01 2026-06-30 0001160420 ADIA:MedicalProceduresMember ADIA:BioleteMember 2026-01-01 2026-06-30 0001160420 ADIA:MedicalProceduresMember ADIA:AdiaMedMember 2026-01-01 2026-06-30 0001160420 ADIA:MedicalProceduresMember ADIA:AdiaLabsMember 2026-01-01 2026-06-30 0001160420 ADIA:SalesOfBiologicsNetOfDiscountsAndRefundsMember us-gaap:CorporateMember 2026-01-01 2026-06-30 0001160420 ADIA:SalesOfBiologicsNetOfDiscountsAndRefundsMember ADIA:BioleteMember 2026-01-01 2026-06-30 0001160420 ADIA:SalesOfBiologicsNetOfDiscountsAndRefundsMember ADIA:AdiaMedMember 2026-01-01 2026-06-30 0001160420 ADIA:SalesOfBiologicsNetOfDiscountsAndRefundsMember ADIA:AdiaLabsMember 2026-01-01 2026-06-30 0001160420 ADIA:SalesOfBiologicsNetOfDiscountsAndRefundsMember 2026-01-01 2026-06-30 0001160420 ADIA:ShippingAndDeliveryMember us-gaap:CorporateMember 2026-01-01 2026-06-30 0001160420 ADIA:ShippingAndDeliveryMember ADIA:BioleteMember 2026-01-01 2026-06-30 0001160420 ADIA:ShippingAndDeliveryMember ADIA:AdiaMedMember 2026-01-01 2026-06-30 0001160420 ADIA:ShippingAndDeliveryMember ADIA:AdiaLabsMember 2026-01-01 2026-06-30 0001160420 us-gaap:CorporateMember 2025-01-01 2025-06-30 0001160420 ADIA:BioleteMember 2025-01-01 2025-06-30 0001160420 ADIA:AdiaMedMember 2025-01-01 2025-06-30 0001160420 ADIA:AdiaLabsMember 2025-01-01 2025-06-30 0001160420 ADIA:MedicalProceduresMember us-gaap:CorporateMember 2025-01-01 2025-06-30 0001160420 ADIA:MedicalProceduresMember ADIA:BioleteMember 2025-01-01 2025-06-30 0001160420 ADIA:MedicalProceduresMember ADIA:AdiaMedMember 2025-01-01 2025-06-30 0001160420 ADIA:MedicalProceduresMember ADIA:AdiaLabsMember 2025-01-01 2025-06-30 0001160420 ADIA:SalesOfBiologicsNetOfDiscountsAndRefundsMember us-gaap:CorporateMember 2025-01-01 2025-06-30 0001160420 ADIA:SalesOfBiologicsNetOfDiscountsAndRefundsMember ADIA:BioleteMember 2025-01-01 2025-06-30 0001160420 ADIA:SalesOfBiologicsNetOfDiscountsAndRefundsMember ADIA:AdiaMedMember 2025-01-01 2025-06-30 0001160420 ADIA:SalesOfBiologicsNetOfDiscountsAndRefundsMember ADIA:AdiaLabsMember 2025-01-01 2025-06-30 0001160420 ADIA:SalesOfBiologicsNetOfDiscountsAndRefundsMember 2025-01-01 2025-06-30 0001160420 ADIA:SalesOfSupplementsMember us-gaap:CorporateMember 2025-01-01 2025-06-30 0001160420 ADIA:SalesOfSupplementsMember ADIA:BioleteMember 2025-01-01 2025-06-30 0001160420 ADIA:SalesOfSupplementsMember ADIA:AdiaMedMember 2025-01-01 2025-06-30 0001160420 ADIA:SalesOfSupplementsMember ADIA:AdiaLabsMember 2025-01-01 2025-06-30 0001160420 us-gaap:ServiceMember us-gaap:CorporateMember 2025-01-01 2025-06-30 0001160420 us-gaap:ServiceMember ADIA:BioleteMember 2025-01-01 2025-06-30 0001160420 us-gaap:ServiceMember ADIA:AdiaMedMember 2025-01-01 2025-06-30 0001160420 us-gaap:ServiceMember ADIA:AdiaLabsMember 2025-01-01 2025-06-30 0001160420 us-gaap:ServiceMember 2025-01-01 2025-06-30 0001160420 us-gaap:CommonStockMember 2024-05-31 0001160420 ADIA:LotusMember us-gaap:CommonStockMember 2024-05-31 0001160420 ADIA:CoombsMember us-gaap:CommonStockMember 2024-05-31 iso4217:USD shares iso4217:USD shares pure ADIA:Integer false --12-31 2026 Q2 0001160420 0 0 0 0 0 0 0 0 0 0.001 0.001 0 0 0 0 3 3 2 2 10-Q true 2026-06-30 false 000-33265 ADIA NUTRITION, INC. NV 35-2829671 1561 West Fairbanks Avenue Suite 205 Winter Park FL 32789 321 788-0850 Yes Yes Non-accelerated Filer true false false 94404696 128115 79392 44010 33360 625 250 140500 140500 25025 29348 23483 342598 161510 79500 79500 71731 72107 30300 25000 10000 10000 33495 30695 96455 108171 79975 107843 401456 433316 744054 594826 5224 2393 153 153 60681 37915 64000 14000 835312 600000 64743 63950 26784 26784 1056897 745195 17267 45918 49671 61387 66938 107305 1123835 852500 0.001 0.001 1 1 1 1 1 1 1 1 0.001 0.001 10000000 10000000 0 0 0.001 0.001 89999999 89999999 1750000 1750000 1750000 1750000 1750 1750 0.001 0.001 800000000 800000000 94404696 94404696 94404696 94404696 94405 94405 0.001 0.001 100000000 0 0 152607 152607 15467045 15467045 -16095589 -15973482 -379781 -257674 744054 594826 0 1091 0 2155 329820 26000 434670 96700 151750 87500 221525 87500 0 2267 0 2267 3815 1288 5465 1288 485385 118146 661660 189910 0 188 0 663 82588 13551 153550 70788 120217 78484 157953 78484 202805 92223 311503 149935 282580 25923 350157 39975 23175 40494 56952 72412 22436 9663 59443 31185 7175 0 12025 0 7723 0 11728 0 6696 4464 13392 11160 81922 46000 160731 93814 2480 0 4920 0 1152 0 2162 0 19748 16130 35931 32002 0 24616 0 24616 55129 0 87731 0 1672 0 2538 0 1443 1143 2695 1916 230751 142510 450248 267105 51829 -116587 -100091 -227130 375 0 750 0 11786 7410 22766 13086 -11411 -7410 -22016 -13086 40418 -123997 -122107 -240216 -0 -0 -0 -0 40418 -123997 -122107 -240216 -0.00 -0.00 -0.00 -0.00 0.00 0 0 0 94404696 89641758 94404696 92770810 161404696 89641758 94404696 92770810 1 1 10000000 10000 1750000 1750 2625000 110357 1 1 10000000 10000 1750000 1750 2625000 110357 -10000000 -10000 14000000 14000 1 1 0 0 1750000 1750 16625000 124357 95899861 95900 0 0 15385550 -15578018 25540 -116219 -116219 95899861 95900 0 0 15385550 -15694237 -90679 -15495165 -15495 25495 56000 70000 -123997 -123997 80404696 80405 0 0 15467045 -15818234 -144676 1 1 0 0 1750000 1750 2875000 152607 1 1 0 0 1750000 1750 2875000 152607 1 1 0 0 1750000 1750 2875000 152607 94404696 94405 0 0 15467045 -15973482 -257674 -162525 -162525 94404696 94405 0 0 15467045 -16136007 -420199 40418 40418 94404696 94405 0 0 15467045 -16095589 -379781 -122107 -240216 2695 1916 27868 25802 11716 8351 11025 2267 -376 -0 5865 -7285 115475 -40116 2831 -1880 22766 13086 50000 0 -27858 -19734 -164078 -167541 5495 13199 5300 -0 -0 3604 -10795 -16803 11716 8351 0 70000 235312 231471 223596 293120 48723 108776 79392 6323 128115 115099 0 0 0 0 0 79500 0 25495 <p id="xdx_800_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zAcj96I0Yxf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 1 – <span id="xdx_82A_zoi13rQQtCkc">ORGANIZATION AND BUSINESS</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ADIA Nutrition Inc. (the “Company,” “we,” “us” or “our”), a Nevada corporation, has a calendar fiscal year and is listed on OTC Markets under the trading symbol ADIA. The Company had abandoned its business and failed to take steps to dissolve, liquidate and distribute its assets. It had also failed to meet the required reporting requirements with the Nevada Secretary of State, hold an annual meeting of stockholders and pay its annual franchise tax from 2013 to 2022 which resulted in its Nevada charter being revoked. The Company also failed to provide adequate current public information as defined in Rule 144, promulgated under the Securities Act of 1933, and was thus subject to revocation by the Securities and Exchange Commission pursuant to Section 12(k) of the Exchange Act. In March 2022, a shareholder filed a petition for custodianship with the District Court, Clark County, Nevada and was appointed as the custodian of the Company in June 2022. The Company’s Nevada charter was reinstated on June 27, 2022, and all required reports were filed with the State of Nevada soon thereafter. The custodian was not able to recover any of the Company’s accounting records from previous management but was able to get the shareholder information hence the Company’s outstanding common shares were reflected in the stockholders’ equity section of the unaudited financial statements for the year ended December 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company was incorporated in the State of Nevada in April 1975 as Domi Associates, Inc. In March 2001, the issuer amended its Articles of Incorporation to change its name to Drilling, Inc. On April 20, 2004, an amendment to the Articles of Incorporation was made to change the name to PIVX Solutions, Inc. In 2012, the issuer changed to ADIA Nutrition, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 14, 2022, UMA LLC, a shareholder of the Company, made a demand to the Company, at the last address of record, to comply with the Nevada Secretary of State statues N.R.S. 78.710 and N.R.S. 78.150. UMA, LLC, made several attempts to locate prior management and reinstate the Company’s Nevada charter, which had been revoked. On, May 6, 2022, UMA, LLC filed a petition against the Company in the District Court of Clark County, Nevada, entitled “In the Matter of ADIA Nutrition Inc., a Nevada corporation”, case number A-22-852241-C, along with an Application for Appointment of Custodian.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 17, 2022, the District Court of Clark County, Nevada entered an Order Granting Application for Appointment of UMA LLC, (the “Order”), as Custodian of the Company. Pursuant to the Order, the UMA LLC (the “Custodian”) has the authority to take any actions on behalf of the Company, which are reasonable, prudent or for the benefit pursuant to, including, but not limited to, issuing shares of stock, and issuing new classes of stock, as well as entering in contracts on behalf of the Company. In addition, the Custodian, pursuant to the Order, is required to meet the requirements under the Nevada charter.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 17, 2022, the Custodian appointed Nikki Lee as the Company’s sole officer and director. The Custodian designated one share of preferred stock as Special 2022 Series A Preferred Stock at par value $0.001. The Special 2022 Series A Preferred stock has <span id="xdx_908_eus-gaap--PreferredStockVotingRights_c20220616__20220617__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z6qyF19Mc9e4" title="Preferred stock voting rights description">60% voting rights</span> over all classes of stock and is convertible into sixty million shares of the Company’s common stock. On June 17, 2022, the Custodian granted to itself, one share of Special Series A Preferred Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 27, 2022, the Company filed a Certificate of Revival with the Secretary State of the State of Nevada, which reinstated the Company’s charter and appointed a new Resident Agent in Nevada.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 5, 2022, in a private transaction, the Custodian entered into a Securities Purchase Agreement (the “SPA”) with Nairobi Anderson, to sell the Special 2022 Series A Preferred stock, and upon closing, Nairobi Anderson acquired 60% voting control of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 27, 2023, Nairobi Anderson entered into an SPA with The Leonard and Elizabeth Greene Family Trust to sell its share of Special 2022 Series A Preferred stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 22, 2024, The Leonard and Elizabeth Greene Family Trust sold its Special 2022 Series A Preferred share to Legends Investments Properties, LLC, 100% owned by Larry Powalisz. Leonard Greene resigned as Director and Larry Powalisz was appointed Chief Executive Officer and Director, and Rebecca Miller was appointed as Chief Financial Officer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>ADIA – Going Forward</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ADIA is dedicated to revolutionizing healthcare through innovative partnerships. The primary focus is to work closely with healthcare providers and health insurance companies to facilitate and provide Autologous Hematopoietic Stem Cell Transplantation (AHSCT) treatments for Multiple Sclerosis (MS) patients.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ADIA engages with health insurance companies to advocate for the inclusion and reimbursement of AHSCT treatments for MS patients. The dedicated team navigates the complexities of insurance processes, striving to make these transformative therapies financially accessible to a wider population.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ADIA envisions a future where AHSCT is a widely accessible and transformative treatment option for MS patients. Through commitment, collaboration, advocacy, and quality care, the Company aims to redefine the standard of treatment for MS and contribute to improved outcomes and quality of life for those affected by the disease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ADIA is also committed to revolutionizing the supplement industry through strategic acquisitions and investments in companies that uphold the highest standards of integrity and quality. The mission is to empower individuals worldwide to prioritize their health and well-being by providing access to premium supplements crafted exclusively from organic ingredients. ADIA has, during the third quarter of 2024, acquired Biolete, LLC (see Note 7 below) and taken an 18% equity position in Cement Factory, LLC (see Note 8 below).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2025, ADIA sold the inventory on hand and the associated trademarks of the Biolete brand to Cement Factory in which is continued to hold its 18% membership interest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Being dedicated to revolutionizing healthcare through innovative partnerships. The primary focus is to work closely with healthcare providers and health insurance companies to facilitate and provide AHSCT treatments for MS patients. In late 2024, ADIA formed Adia Med of Winter Park, LLC as the clinic to perform the aforementioned treatments, and Adia Labs, LLC which will procure and sell the products relating to these procedures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ADIA strives to cultivate a portfolio of brands that exemplify excellence, transparency, and sustainability, ensuring that every product that it offers contributes to the enhancement of the consumers lives.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>ADIA Nutrition – Board of Directors Expansion</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 19, 2024, the Company appointed Monica Sher, MD as a Director of Company. The Company will issue <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20240818__20240819__us-gaap--NonmonetaryTransactionTypeAxis__custom--SharesToBeIssuedMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--MonicaSherMember_zBDBo2pnbhZ3" title="Shares issued for compensation, shares">250,000</span> shares of its Series C Preferred Stock at a future date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 10, 2024, the Company appointed Richard Edwards, DO as a Director of Company. The Company will issue <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20240909__20240910__us-gaap--NonmonetaryTransactionTypeAxis__custom--SharesToBeIssuedMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--RichardEdwardsMember_zviZ1llLW6vg" title="Shares issued for compensation, shares">250,000</span> shares of its Series C Preferred Stock at a future date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 23, 2024, the Company appointed Kalpesh Barot, MD as a Director of Company. The Company will issue <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20240922__20240923__us-gaap--NonmonetaryTransactionTypeAxis__custom--SharesToBeIssuedMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--KalpeshBarotMember_zxdm2ZvYUxY4" title="Shares issued for compensation, shares">250,000</span> shares of its Series C Preferred Stock at a future date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 13, 2025, the Company appointed Dr. Evan Thomas, MD, PhD. as an Independent Medical Director for the Company’s medical division, Adia Med. The Company will issue <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20251012__20251013__us-gaap--NonmonetaryTransactionTypeAxis__custom--SharesToBeIssuedMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--EvanThomasMember_zaQTwR8DwmJc" title="Shares issued for compensation, shares">250,000</span> shares of its Series C Preferred Stock at a future date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> 60% voting rights 250000 250000 250000 250000 <p id="xdx_80C_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zVBfa1Ly6paa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 2 – <span id="xdx_82B_zvU5YcmC6ZA2">GOING CONCERN</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company generated revenues of $<span id="xdx_902_eus-gaap--Revenues_c20260101__20260630_zE5XFDFAXPHh" title="Revenues">661,660</span> for the six months ended June 30, 2026, with an associated net loss of $<span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_di_c20260101__20260630_z2yfzNaCRcWi" title="Net income (loss)">122,107</span>, and at June 30, 2026, the Company has an accumulated deficit of $<span id="xdx_907_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20260630_zA5DH0S89Tm9" title="Accumulated deficit">16,095,589</span>. The Company did generate a net income of $<span id="xdx_904_eus-gaap--NetIncomeLoss_c20260401__20260630_z8QhEChP4Ne8" title="Net income (loss)">40,418</span> for the three months ended June 30, 2026, in addition to significantly higher revenue during the three months ended June 30, 2026 versus the three months ended March 31, 2026. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The Company’s continuation as a going concern for one year after the audit report is dependent upon, among other things, its ability to generate greater revenues and its ability to obtain capital from third parties. No assurance can be given that the Company will be successful in these efforts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management anticipates continued growth in revenue and plans to utilize the funding resources it has available (i.e., its line of credit facility) as well as the continued identification of adequate sources of funding to provide bridge capital, financing of receivables, and operating capital for continued growth.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> 661660 -122107 -16095589 40418 <p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_ziV5ot5U031g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 3 – <span id="xdx_824_zWLrKgRSGzq">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zqgGml5Lvi12" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86D_zTQQiorITdrh">Basis of Presentation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management further acknowledges that it is solely responsible for adopting sound accounting practices, establishing and maintaining a system of internal accounting control and preventing and detecting fraud. The Company's system of internal accounting control is designed to assure, among other items, that (1) recorded transactions are valid; (2) valid transactions are recorded; and (3) transactions are recorded in the proper period in a timely manner to produce consolidated financial statements which present fairly the financial condition, results of operations and cash flows of the Company for the respective periods being presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84F_eus-gaap--UseOfEstimates_zl1Wr2Jhh03b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_862_z3T5FCNXufj1">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zLFneq5uvqo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><span id="xdx_86F_zCVk5lEfttyh">Principles of Consolidation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements have been prepared in accordance with GAAP. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries (Adia Labs, LLC and Adia Med of Winter Park, LLC). All intercompany balances and transactions have been eliminated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z4qbdP5iiApg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86C_zHsxH5CKljX">Cash and Cash Equivalents</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for cash and cash equivalents under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 305, “<i>Cash and Cash Equivalents,</i>” and considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_848_eus-gaap--AdvertisingCostsPolicyTextBlock_z8omz3Vb2WF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86D_z9NIiIfw2Ztb">Advertising and Promotion Costs</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advertising and promotion costs are expensed as incurred. These expenses were $<span id="xdx_90C_eus-gaap--MarketingAndAdvertisingExpense_c20260401__20260630_zUE4z8grhuqd" title="Advertising and promotion">22,436</span> and $<span id="xdx_905_eus-gaap--MarketingAndAdvertisingExpense_c20250401__20250630_z8MCGLnv6kd9" title="Advertising and promotion">9,663</span> for the three months ended June 30, 2026 and 2025, respectively, and $<span id="xdx_90D_eus-gaap--MarketingAndAdvertisingExpense_c20260101__20260630_zUp90XKY9Q3j" title="Advertising and promotion">59,443</span>, and $<span id="xdx_901_eus-gaap--MarketingAndAdvertisingExpense_c20250101__20250630_zohLyLqaDqbb" title="Advertising and promotion">31,185</span> for the six months ended June 30, 2026 and 2025, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--RevenueRecognitionPolicyTextBlock_zeMzxgIMYepg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_868_zWFFmX24wSUj">Revenue Recognition</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records transactions in accordance with ASU 2014-09, <i>“Revenue from Contracts with Customers”</i> and all subsequent amendments to the ASU (collectively, “ASC 606”). In accordance with ASC 606, revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operations currently generate revenues from the sale of our biologic products, the performance of medical procedures, sales of ancillary products, shipping and delivery, and other services. During the six months ended June 30, 2026 and 2025, the Company had revenues of $<span id="xdx_907_eus-gaap--Revenues_c20260101__20260630_zbRwYx4fWG9c" title="Revenues">661,660</span> and $<span id="xdx_906_eus-gaap--Revenues_c20250101__20250630_zNaoROwtK5El" title="Revenues">189,910</span>, respectively. Revenue was generated from the following sources:</p> <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--DisaggregationOfRevenueTableTextBlock_zbq6TDUeXyl3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Revenue Recognition)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B9_zU9GVWGb5XDa" style="display: none">Schedule of revenue recognition</span></td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%">Sales of supplements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--Revenues_d0_c20260101__20260630__srt--ProductOrServiceAxis__custom--SalesOfSupplementsMember_z4ush9ENimmk" style="width: 11%; text-align: right" title="Total Revenue">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--SalesOfSupplementsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zerikQmchsc8" title="Concentration risk, percentage">0.0</span>%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20250101__20250630__srt--ProductOrServiceAxis__custom--SalesOfSupplementsMember_zZNX9ocgUKy4" style="width: 11%; text-align: right">2,155</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--SalesOfSupplementsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zthlePvS2g9g" title="Concentration risk, percentage">1.1</span>%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Medical procedures</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--Revenues_c20260101__20260630__srt--ProductOrServiceAxis__custom--MedicalProceduresMember_zrLedfUWlqXj" style="text-align: right">434,670</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--MedicalProceduresMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zx4DmJciPDxb" title="Concentration risk, percentage">65.7</span>%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--Revenues_d0_c20250101__20250630__srt--ProductOrServiceAxis__custom--MedicalProceduresMember_z6CtUd3zOZS7" style="text-align: right">96,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--MedicalProceduresMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zA0ZJ74WsLX1" title="Concentration risk, percentage">50.9</span>%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Sales of biologics</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--Revenues_c20260101__20260630__srt--ProductOrServiceAxis__custom--SalesOfBiologicsMember_zNRbdVKJxGx6" style="text-align: right">221,525</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--SalesOfBiologicsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zI3ZPby4g1Jk" title="Concentration risk, percentage">33.5</span>%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--Revenues_d0_c20250101__20250630__srt--ProductOrServiceAxis__custom--SalesOfBiologicsMember_z4Cum7itMehk" style="text-align: right">87,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--SalesOfBiologicsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zqzcyCAa6KJl" title="Concentration risk, percentage">46.1</span>%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Services</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--Revenues_d0_c20260101__20260630__srt--ProductOrServiceAxis__custom--ServicesMember_zo2ldy4pIb0c" style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp0_c20260101__20260630__srt--ProductOrServiceAxis__custom--ServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zufhlqR0Mtuc" title="Concentration risk, percentage">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--Revenues_d0_c20250101__20250630__srt--ProductOrServiceAxis__custom--ServicesMember_zluOV7PnxVj9" style="text-align: right">2,267</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--ServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zlQpIbkPWYgi" title="Concentration risk, percentage">1.2</span>%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Shipping and delivery</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--Revenues_c20260101__20260630__srt--ProductOrServiceAxis__custom--ShippingAndDeliveryMember_zS91Bm5i0GI7" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">5,465</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--ShippingAndDeliveryMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z9gLCOixhho1" title="Concentration risk, percentage">0.8</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--Revenues_d0_c20250101__20250630__srt--ProductOrServiceAxis__custom--ShippingAndDeliveryMember_zlDjBehu8Pvf" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">1,288</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--ShippingAndDeliveryMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zo766aFSGBFg" title="Concentration risk, percentage">0.7</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Revenue</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--Revenues_c20260101__20260630_zoKKOnkDbjza" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total Revenue">661,660</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--TotalRevenueMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zgpIQLBEaV01" title="Percentage of revenue">100.0</span>%</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20250101__20250630_ztfM0x6J0mH8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total Revenue">189,910</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--TotalRevenueMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zXlZbUN8kl24" title="Percentage of revenue">100.0</span>%</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zCqPB7u8VcT3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_841_eus-gaap--CostOfSalesPolicyTextBlock_zHdpFPZkwVR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><span id="xdx_863_zeJwpetzkKu">Costs of Revenues</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our policy is to recognize costs of revenue in the same manner in conjunction with revenue recognition. Cost of revenues include the costs directly attributable to revenue. Cost of revenue was the cost of our supplement products, the fees associated with the administration of medical procedures, and costs of our biologic products. For the six months ended June 30, 2026 and 2025, cost of revenue was $<span id="xdx_900_eus-gaap--CostOfRevenue_c20260101__20260630_zBQ2eW0JE2nd" title="Cost of revenue">311,503</span> and $<span id="xdx_90D_eus-gaap--CostOfRevenue_c20250101__20250630_znE5tGPPE6q8" title="Cost of revenue">149,935</span>, respectively. Cost of revenue was as a result of the following:</p> <table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfNetBenefitCostsTableTextBlock_zmbwtMi2Cu1e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Costs of Revenues)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B3_zSuBlxVAxTbf" style="display: none">Schedule of costs of revenues</span></td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%">Cost of supplements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--CostOfRevenue_d0_c20260101__20260630__srt--ProductOrServiceAxis__custom--CostOfSupplementsMember_zih9yfbDUTxb" style="width: 11%; text-align: right" title="Total Cost of Revenue">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--CostOfSupplementsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z2g72jhWdcij" title="Concentration risk, percentage">0.0</span>%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CostOfRevenue_c20250101__20250630__srt--ProductOrServiceAxis__custom--CostOfSupplementsMember_zDISvJacI2ce" style="width: 11%; text-align: right">663</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--CostOfSupplementsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zlKiZolN3kHd" title="Concentration risk, percentage">0.4</span>%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cost for administration of medical procedures</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--CostOfRevenue_c20260101__20260630__srt--ProductOrServiceAxis__custom--CostForAdministrationOfMedicalProceduresMember_zy7iQ6sppmui" style="text-align: right">153,550</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--CostForAdministrationOfMedicalProceduresMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zZMbRhuKhXj9" title="Concentration risk, percentage">49.3</span>%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--CostOfRevenue_d0_c20250101__20250630__srt--ProductOrServiceAxis__custom--CostForAdministrationOfMedicalProceduresMember_zYDQpTFvUmJl" style="text-align: right">70,788</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--CostForAdministrationOfMedicalProceduresMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zwxQmexLpFge" title="Concentration risk, percentage">47.2</span>%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Cost of biologics</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--CostOfRevenue_c20260101__20260630__srt--ProductOrServiceAxis__custom--CostOfBiologicsMember_z16mlobcJG8b" style="border-bottom: Black 1pt solid; text-align: right">157,953</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--CostOfBiologicsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zLbouDbdHQki" title="Concentration risk, percentage">50.7</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--CostOfRevenue_d0_c20250101__20250630__srt--ProductOrServiceAxis__custom--CostOfBiologicsMember_zuNK0pPxSiSf" style="border-bottom: Black 1pt solid; text-align: right">78,484</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--CostOfBiologicsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zllTwlOtWnee" title="Concentration risk, percentage">52.4</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Cost of Revenue</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--CostOfRevenue_c20260101__20260630_zfRvpC9umPd7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total Cost of Revenue">311,503</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--TotalCostOfRevenueMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zE5MFdFXl8Mb" title="Concentration risk, percentage">100.0</span>%</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--CostOfRevenue_c20250101__20250630_zBuSokyVtQhk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total Cost of Revenue">149,935</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--TotalCostOfRevenueMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zq3NxBV20cCb" title="Concentration risk, percentage">100.0</span>%</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zMJrvU5fi3Dg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84E_eus-gaap--RegulatoryIncomeTaxesPolicy_zAGOD6FXduzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_866_zUpwG1Adbwdh">Income Taxes and Valuation Allowance</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes under ASC 740, “<i>Income Taxes”</i>. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. All of the Company’s deferred tax assets were offset by a full valuation allowance for June 30, 2026 and December 31, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zdXpaqOweaa8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_867_zO4scRdZJcaf">Financial Instruments</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820, <i>“Fair Value Measurements and Disclosures,”</i> defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.6in"> </td> <td style="width: 0.6in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 -</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 -</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 -</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs that are both significant to the fair value measurement and unobservable.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2026. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not have any assets or liabilities measured at fair value on a recurring basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_849_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zuIBNdPrQBPc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86B_zBveoXye9Zte">Related Parties</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows ASC 850-10, <i>“Related Party Disclosures,” </i>for the identification of related parties and disclosure of related party transactions. The Company leases office space from an entity that is controlled by the CEO and Director of the Company. In addition this related party has provided working capital to the Company on the line of credit facility it has extended to the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) principal owners of the Company; c) management of the Company; d) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and e) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Material related party transactions are required to be disclosed in the consolidated financial statements, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a) the nature of the relationship(s) involved; b) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which statements of operation are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c) the dollar amounts of transactions for each of the periods for which statements of operations are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zP5anoww4LUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86C_z7RSUEidaPi6">Commitments and Contingencies</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows ASC 450-20, “<i>Loss Contingencies</i>,” to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zSLUFirPqkle" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_864_zaVTf4o3FBrh">Earnings (loss) per share</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic income (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average common shares outstanding for the period. Diluted income (loss) per share is computed giving effect to all potentially dilutive common shares. Potentially dilutive common shares may consist of incremental shares issuable upon the exercise of stock options and warrants and upon the conversion of notes. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. The number of potentially dilutive common shares (if the preferred shares were converted) for the three and six months ended June 30, 2026 and 2025, are <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260401__20260630_zkuD9oTKjFaj" title="Potentially dilutive common shares"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630_zBx3Y7ztUNba" title="Potentially dilutive common shares"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250401__20250630_zWwT6400TrY7" title="Potentially dilutive common shares"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630_z3CN9fNyVDi4" title="Potentially dilutive common shares">67,000,000</span></span></span></span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--InventoryPolicyTextBlock_z35ghWBFnrNj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86C_zpcViRPBrlPg">Inventory</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are carried at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of applicable variable selling expenses. Management periodically evaluates if a reserve is necessary, and management determined that a reserve was not necessary at June 30, 2026 and December 31, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--InvestmentPolicyTextBlock_zdYn5g2fuYtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_862_zBWq0RfnP9z9">Investments</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 321, <i>“Investments – Equity Securities,”</i> our investment in Cement Factory, LLC is stated at cost, as our investment in this entity constitutes less than 20% in Cement Factory, LLC and does not provide the Company control over this entity. The original agreement entered into was rescinded, and replaced with an agreement to acquire an 18% membership interest in Cement Factory, LLC, allowing the Company to receive an <span id="xdx_908_eus-gaap--InvestmentCompanyTotalReturn_dp_c20260101__20260630__srt--OwnershipAxis__custom--CementFactoryLLCMember_zlOxN0o2fRNa" title="Dividend percentage">18</span>% dividend income from Cement Factory paid annually at the end of each calendar year based on profitability. (See Note 8.)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_z6bzTwvfmmFg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_864_zlzwHCRxBI7j">Leases</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, <i>“Leases”</i> Topic 842, which amends the guidance in former ASC Topic 840, Leases (“ASC 840”). The new standard increases transparency and comparability most significantly by requiring the recognition by lessees of right-of-use (“ROU”) assets and lease liabilities on the balance sheet for all leases longer than 12 months. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. For lessees, leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement, over the expected term on a straight-line basis. We determine if an arrangement is a lease at inception. The Company recognizes ROU assets and lease liabilities for leases with terms greater than 12 months or leases that contain a purchase option that is reasonably certain to be exercised. Leases are classified as either finance or operating leases. This classification dictates whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. Operating leases are included in operating lease ROU assets and operating lease liabilities on our consolidated balance sheets. Finance leases are included in finance lease assets, current finance lease liabilities, and long-term finance lease liabilities on our consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s ROU assets and lease liabilities are recognized on the lease commencement date in an amount that represents the present value of future lease payments over the lease term. The Company utilizes its collateralized incremental borrowing rate commensurate to the lease term as the discount rate for its leases unless the Company can specifically determine the lessor’s implicit rate. Certain lease contracts contain non-lease components such as maintenance and utilities. The Company has made a policy election to not separate the lease and non-lease components, and thus recognize a single lease component for all of its right-of-use assets and liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In evaluating contracts to determine if they qualify as a lease, the Company considers factors such as if it has obtained substantially all of the rights to the underlying asset through exclusivity, if the Company can direct the use of the asset by making decisions about how and for what purpose the asset will be used and if the lessor has substantive substitution rights. Furthermore, the Company assesses whether it is reasonably certain to exercise options to extend or terminate a lease considering all relevant factors that create economic incentive to exercise such options, including asset, contract, market, and entity-based factors. These evaluations may require significant judgment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_845_ecustom--LossContingenciesPolicyTextBlock_zSBEeF2dKB3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><span id="xdx_863_zxsUhBiCYwN6">Loss Contingencies</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time the Company may be subject to various legal proceedings and claims that arise in the ordinary course of business. On at least a quarterly basis, consistent with ASC 450-20-50-1C, if the Company determines that there is a reasonable possibility that a material loss may have been incurred, or is reasonably estimable, regardless of whether the Company accrued for such a loss (or any portion of that loss), the Company will confer with its legal counsel, consistent with ASC 450. If the material loss is determinable or reasonably estimable, the Company will record it in its accounts and as a liability on the consolidated balance sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z3mh11FwVdAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_868_zHfLC5dxqMm">Fixed Assets</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows ASC 360, “<i>Property, Plant, and Equipment,”</i> for its fixed assets. Equipment is stated at cost less accumulated depreciation. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets (<span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__srt--RangeAxis__srt--MinimumMember_z9HAsyaqUfCb" title="Estimated useful lives">3</span> to <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__srt--RangeAxis__srt--MaximumMember_z6SawKQq0c7h" title="Estimated useful lives">7</span> years for equipment). Depreciation expense for the three months ended June 30, 2026 and 2025, was $<span id="xdx_906_eus-gaap--Depreciation_c20260401__20260630_zHNbcHWMEA23" title="Depreciation">1,443</span> and $<span id="xdx_90C_eus-gaap--Depreciation_c20250401__20250630_z5GwqoK3ZvQh" title="Depreciation">1,143</span>, respectively, and $<span id="xdx_902_eus-gaap--Depreciation_c20260101__20260630_zAU81hNTO2oe" title="Depreciation">2,695</span> and $<span id="xdx_908_eus-gaap--Depreciation_c20250101__20250630_zIvZf6AaZtp4" title="Depreciation">1,916</span> for the six months ended June 30, 2026 and 2025, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zSUUhSe7wMEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zM4Wd38VkV6e">Long-lived Assets</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-lived assets such as fixed assets and identifiable intangibles are reviewed for impairment whenever facts and circumstances indicate that the carrying value may not be recoverable. When required impairment losses on assets to be held and used are recognized based on the fair value of the asset. The fair value is determined based on estimates of future cash flows, market value of similar assets, if available, or independent appraisals, if required. If the carrying amount of the long-lived asset is not recoverable from its undiscounted cash flows, an impairment loss is recognized for the difference between the carrying amount and fair value of the asset. When fair values are not available, the Company estimates fair value using the expected future cash flows discounted at a rate commensurate with the risk associated with the recovery of the assets. We did not recognize any impairment losses for any periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zZ6HPeinZh39" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_863_z8g0pES2Oi3l">Segment Reporting</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating segments are components of an enterprise about which separate financial information is available and is evaluated regularly by management, namely the Chief Operating Decision Maker (“CODM”) of an organization, in order to determine operating and resource allocation decisions. By this definition, the Company has identified its Chief Executive Officer as the CODM. The CODM has identified Adia Labs and Adia Med as the Company’s operating segments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z3ugzOEZ80Nf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_862_zXKtyKNYYPGf">Stock-Based Compensation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 718 <i>“Compensation – Stock Compensation,”</i> prescribes accounting and reporting standards for all stock-based payments award to employees, including employee stock options, restricted stock, employee stock purchase plans and stock appreciation rights, may be classified as either equity or liabilities. The Company determines if a present obligation to settle the share-based payment transaction in cash or other assets exists. A present obligation to settle in cash or other assets exists if: (a) the option to settle by issuing equity instruments lacks commercial substance or (b) the present obligation is implied because of an entity’s past practices or stated policies. If a present obligation exists, the transaction should be recognized as a liability; otherwise, the transaction should be recognized as equity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of FASB ASC 505-50 “<i>Equity – Based Payments to Non-Employees</i>.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date. For the three months ended June 30, 2026 and 2025, the Company did <span id="xdx_90E_eus-gaap--ShareBasedCompensation_do_c20260401__20260630_zxgscDZPWee1" title="Share-based compensation"><span id="xdx_90A_eus-gaap--ShareBasedCompensation_do_c20250401__20250630_z6tIQhd8rJMf" title="Share-based compensation">no</span></span>t have any share-based compensation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zy2cvv7CCyrd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_867_zKJ6j5tf2wsl">Recently Issued Accounting Pronouncements</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the corporation’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration. For the year ended December 31, 2025, we adopted the ASU 2023-09, <i>“Income Taxes (Topic 740) Improvement to Income Tax Disclosure”</i>, to appropriately reconcile to specific tax rate provisions. As a result, certain prior year amounts have been reclassified for consistency with current year presentation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zqgGml5Lvi12" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86D_zTQQiorITdrh">Basis of Presentation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management further acknowledges that it is solely responsible for adopting sound accounting practices, establishing and maintaining a system of internal accounting control and preventing and detecting fraud. The Company's system of internal accounting control is designed to assure, among other items, that (1) recorded transactions are valid; (2) valid transactions are recorded; and (3) transactions are recorded in the proper period in a timely manner to produce consolidated financial statements which present fairly the financial condition, results of operations and cash flows of the Company for the respective periods being presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84F_eus-gaap--UseOfEstimates_zl1Wr2Jhh03b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_862_z3T5FCNXufj1">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zLFneq5uvqo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><span id="xdx_86F_zCVk5lEfttyh">Principles of Consolidation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements have been prepared in accordance with GAAP. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries (Adia Labs, LLC and Adia Med of Winter Park, LLC). All intercompany balances and transactions have been eliminated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z4qbdP5iiApg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86C_zHsxH5CKljX">Cash and Cash Equivalents</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for cash and cash equivalents under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 305, “<i>Cash and Cash Equivalents,</i>” and considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_848_eus-gaap--AdvertisingCostsPolicyTextBlock_z8omz3Vb2WF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86D_z9NIiIfw2Ztb">Advertising and Promotion Costs</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advertising and promotion costs are expensed as incurred. These expenses were $<span id="xdx_90C_eus-gaap--MarketingAndAdvertisingExpense_c20260401__20260630_zUE4z8grhuqd" title="Advertising and promotion">22,436</span> and $<span id="xdx_905_eus-gaap--MarketingAndAdvertisingExpense_c20250401__20250630_z8MCGLnv6kd9" title="Advertising and promotion">9,663</span> for the three months ended June 30, 2026 and 2025, respectively, and $<span id="xdx_90D_eus-gaap--MarketingAndAdvertisingExpense_c20260101__20260630_zUp90XKY9Q3j" title="Advertising and promotion">59,443</span>, and $<span id="xdx_901_eus-gaap--MarketingAndAdvertisingExpense_c20250101__20250630_zohLyLqaDqbb" title="Advertising and promotion">31,185</span> for the six months ended June 30, 2026 and 2025, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 22436 9663 59443 31185 <p id="xdx_847_eus-gaap--RevenueRecognitionPolicyTextBlock_zeMzxgIMYepg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_868_zWFFmX24wSUj">Revenue Recognition</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records transactions in accordance with ASU 2014-09, <i>“Revenue from Contracts with Customers”</i> and all subsequent amendments to the ASU (collectively, “ASC 606”). In accordance with ASC 606, revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operations currently generate revenues from the sale of our biologic products, the performance of medical procedures, sales of ancillary products, shipping and delivery, and other services. During the six months ended June 30, 2026 and 2025, the Company had revenues of $<span id="xdx_907_eus-gaap--Revenues_c20260101__20260630_zbRwYx4fWG9c" title="Revenues">661,660</span> and $<span id="xdx_906_eus-gaap--Revenues_c20250101__20250630_zNaoROwtK5El" title="Revenues">189,910</span>, respectively. Revenue was generated from the following sources:</p> <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--DisaggregationOfRevenueTableTextBlock_zbq6TDUeXyl3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Revenue Recognition)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B9_zU9GVWGb5XDa" style="display: none">Schedule of revenue recognition</span></td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%">Sales of supplements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--Revenues_d0_c20260101__20260630__srt--ProductOrServiceAxis__custom--SalesOfSupplementsMember_z4ush9ENimmk" style="width: 11%; text-align: right" title="Total Revenue">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--SalesOfSupplementsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zerikQmchsc8" title="Concentration risk, percentage">0.0</span>%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20250101__20250630__srt--ProductOrServiceAxis__custom--SalesOfSupplementsMember_zZNX9ocgUKy4" style="width: 11%; text-align: right">2,155</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--SalesOfSupplementsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zthlePvS2g9g" title="Concentration risk, percentage">1.1</span>%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Medical procedures</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--Revenues_c20260101__20260630__srt--ProductOrServiceAxis__custom--MedicalProceduresMember_zrLedfUWlqXj" style="text-align: right">434,670</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--MedicalProceduresMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zx4DmJciPDxb" title="Concentration risk, percentage">65.7</span>%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--Revenues_d0_c20250101__20250630__srt--ProductOrServiceAxis__custom--MedicalProceduresMember_z6CtUd3zOZS7" style="text-align: right">96,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--MedicalProceduresMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zA0ZJ74WsLX1" title="Concentration risk, percentage">50.9</span>%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Sales of biologics</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--Revenues_c20260101__20260630__srt--ProductOrServiceAxis__custom--SalesOfBiologicsMember_zNRbdVKJxGx6" style="text-align: right">221,525</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--SalesOfBiologicsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zI3ZPby4g1Jk" title="Concentration risk, percentage">33.5</span>%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--Revenues_d0_c20250101__20250630__srt--ProductOrServiceAxis__custom--SalesOfBiologicsMember_z4Cum7itMehk" style="text-align: right">87,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--SalesOfBiologicsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zqzcyCAa6KJl" title="Concentration risk, percentage">46.1</span>%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Services</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--Revenues_d0_c20260101__20260630__srt--ProductOrServiceAxis__custom--ServicesMember_zo2ldy4pIb0c" style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp0_c20260101__20260630__srt--ProductOrServiceAxis__custom--ServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zufhlqR0Mtuc" title="Concentration risk, percentage">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--Revenues_d0_c20250101__20250630__srt--ProductOrServiceAxis__custom--ServicesMember_zluOV7PnxVj9" style="text-align: right">2,267</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--ServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zlQpIbkPWYgi" title="Concentration risk, percentage">1.2</span>%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Shipping and delivery</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--Revenues_c20260101__20260630__srt--ProductOrServiceAxis__custom--ShippingAndDeliveryMember_zS91Bm5i0GI7" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">5,465</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--ShippingAndDeliveryMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z9gLCOixhho1" title="Concentration risk, percentage">0.8</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--Revenues_d0_c20250101__20250630__srt--ProductOrServiceAxis__custom--ShippingAndDeliveryMember_zlDjBehu8Pvf" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">1,288</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--ShippingAndDeliveryMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zo766aFSGBFg" title="Concentration risk, percentage">0.7</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Revenue</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--Revenues_c20260101__20260630_zoKKOnkDbjza" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total Revenue">661,660</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--TotalRevenueMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zgpIQLBEaV01" title="Percentage of revenue">100.0</span>%</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20250101__20250630_ztfM0x6J0mH8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total Revenue">189,910</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--TotalRevenueMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zXlZbUN8kl24" title="Percentage of revenue">100.0</span>%</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zCqPB7u8VcT3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 661660 189910 <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--DisaggregationOfRevenueTableTextBlock_zbq6TDUeXyl3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Revenue Recognition)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B9_zU9GVWGb5XDa" style="display: none">Schedule of revenue recognition</span></td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%">Sales of supplements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--Revenues_d0_c20260101__20260630__srt--ProductOrServiceAxis__custom--SalesOfSupplementsMember_z4ush9ENimmk" style="width: 11%; text-align: right" title="Total Revenue">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--SalesOfSupplementsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zerikQmchsc8" title="Concentration risk, percentage">0.0</span>%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20250101__20250630__srt--ProductOrServiceAxis__custom--SalesOfSupplementsMember_zZNX9ocgUKy4" style="width: 11%; text-align: right">2,155</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--SalesOfSupplementsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zthlePvS2g9g" title="Concentration risk, percentage">1.1</span>%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Medical procedures</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--Revenues_c20260101__20260630__srt--ProductOrServiceAxis__custom--MedicalProceduresMember_zrLedfUWlqXj" style="text-align: right">434,670</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--MedicalProceduresMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zx4DmJciPDxb" title="Concentration risk, percentage">65.7</span>%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--Revenues_d0_c20250101__20250630__srt--ProductOrServiceAxis__custom--MedicalProceduresMember_z6CtUd3zOZS7" style="text-align: right">96,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--MedicalProceduresMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zA0ZJ74WsLX1" title="Concentration risk, percentage">50.9</span>%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Sales of biologics</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--Revenues_c20260101__20260630__srt--ProductOrServiceAxis__custom--SalesOfBiologicsMember_zNRbdVKJxGx6" style="text-align: right">221,525</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--SalesOfBiologicsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zI3ZPby4g1Jk" title="Concentration risk, percentage">33.5</span>%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--Revenues_d0_c20250101__20250630__srt--ProductOrServiceAxis__custom--SalesOfBiologicsMember_z4Cum7itMehk" style="text-align: right">87,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--SalesOfBiologicsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zqzcyCAa6KJl" title="Concentration risk, percentage">46.1</span>%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Services</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--Revenues_d0_c20260101__20260630__srt--ProductOrServiceAxis__custom--ServicesMember_zo2ldy4pIb0c" style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp0_c20260101__20260630__srt--ProductOrServiceAxis__custom--ServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zufhlqR0Mtuc" title="Concentration risk, percentage">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--Revenues_d0_c20250101__20250630__srt--ProductOrServiceAxis__custom--ServicesMember_zluOV7PnxVj9" style="text-align: right">2,267</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--ServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zlQpIbkPWYgi" title="Concentration risk, percentage">1.2</span>%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Shipping and delivery</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--Revenues_c20260101__20260630__srt--ProductOrServiceAxis__custom--ShippingAndDeliveryMember_zS91Bm5i0GI7" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">5,465</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--ShippingAndDeliveryMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z9gLCOixhho1" title="Concentration risk, percentage">0.8</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--Revenues_d0_c20250101__20250630__srt--ProductOrServiceAxis__custom--ShippingAndDeliveryMember_zlDjBehu8Pvf" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">1,288</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--ShippingAndDeliveryMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zo766aFSGBFg" title="Concentration risk, percentage">0.7</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Revenue</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--Revenues_c20260101__20260630_zoKKOnkDbjza" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total Revenue">661,660</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--TotalRevenueMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zgpIQLBEaV01" title="Percentage of revenue">100.0</span>%</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20250101__20250630_ztfM0x6J0mH8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total Revenue">189,910</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--TotalRevenueMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zXlZbUN8kl24" title="Percentage of revenue">100.0</span>%</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 0 0.000 2155 0.011 434670 0.657 96700 0.509 221525 0.335 87500 0.461 0 0 2267 0.012 5465 0.008 1288 0.007 661660 1.000 189910 1.000 <p id="xdx_841_eus-gaap--CostOfSalesPolicyTextBlock_zHdpFPZkwVR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><span id="xdx_863_zeJwpetzkKu">Costs of Revenues</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our policy is to recognize costs of revenue in the same manner in conjunction with revenue recognition. Cost of revenues include the costs directly attributable to revenue. Cost of revenue was the cost of our supplement products, the fees associated with the administration of medical procedures, and costs of our biologic products. For the six months ended June 30, 2026 and 2025, cost of revenue was $<span id="xdx_900_eus-gaap--CostOfRevenue_c20260101__20260630_zBQ2eW0JE2nd" title="Cost of revenue">311,503</span> and $<span id="xdx_90D_eus-gaap--CostOfRevenue_c20250101__20250630_znE5tGPPE6q8" title="Cost of revenue">149,935</span>, respectively. Cost of revenue was as a result of the following:</p> <table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfNetBenefitCostsTableTextBlock_zmbwtMi2Cu1e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Costs of Revenues)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B3_zSuBlxVAxTbf" style="display: none">Schedule of costs of revenues</span></td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%">Cost of supplements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--CostOfRevenue_d0_c20260101__20260630__srt--ProductOrServiceAxis__custom--CostOfSupplementsMember_zih9yfbDUTxb" style="width: 11%; text-align: right" title="Total Cost of Revenue">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--CostOfSupplementsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z2g72jhWdcij" title="Concentration risk, percentage">0.0</span>%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CostOfRevenue_c20250101__20250630__srt--ProductOrServiceAxis__custom--CostOfSupplementsMember_zDISvJacI2ce" style="width: 11%; text-align: right">663</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--CostOfSupplementsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zlKiZolN3kHd" title="Concentration risk, percentage">0.4</span>%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cost for administration of medical procedures</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--CostOfRevenue_c20260101__20260630__srt--ProductOrServiceAxis__custom--CostForAdministrationOfMedicalProceduresMember_zy7iQ6sppmui" style="text-align: right">153,550</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--CostForAdministrationOfMedicalProceduresMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zZMbRhuKhXj9" title="Concentration risk, percentage">49.3</span>%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--CostOfRevenue_d0_c20250101__20250630__srt--ProductOrServiceAxis__custom--CostForAdministrationOfMedicalProceduresMember_zYDQpTFvUmJl" style="text-align: right">70,788</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--CostForAdministrationOfMedicalProceduresMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zwxQmexLpFge" title="Concentration risk, percentage">47.2</span>%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Cost of biologics</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--CostOfRevenue_c20260101__20260630__srt--ProductOrServiceAxis__custom--CostOfBiologicsMember_z16mlobcJG8b" style="border-bottom: Black 1pt solid; text-align: right">157,953</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--CostOfBiologicsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zLbouDbdHQki" title="Concentration risk, percentage">50.7</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--CostOfRevenue_d0_c20250101__20250630__srt--ProductOrServiceAxis__custom--CostOfBiologicsMember_zuNK0pPxSiSf" style="border-bottom: Black 1pt solid; text-align: right">78,484</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--CostOfBiologicsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zllTwlOtWnee" title="Concentration risk, percentage">52.4</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Cost of Revenue</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--CostOfRevenue_c20260101__20260630_zfRvpC9umPd7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total Cost of Revenue">311,503</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--TotalCostOfRevenueMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zE5MFdFXl8Mb" title="Concentration risk, percentage">100.0</span>%</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--CostOfRevenue_c20250101__20250630_zBuSokyVtQhk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total Cost of Revenue">149,935</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--TotalCostOfRevenueMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zq3NxBV20cCb" title="Concentration risk, percentage">100.0</span>%</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zMJrvU5fi3Dg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 311503 149935 <table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfNetBenefitCostsTableTextBlock_zmbwtMi2Cu1e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Costs of Revenues)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B3_zSuBlxVAxTbf" style="display: none">Schedule of costs of revenues</span></td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%">Cost of supplements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--CostOfRevenue_d0_c20260101__20260630__srt--ProductOrServiceAxis__custom--CostOfSupplementsMember_zih9yfbDUTxb" style="width: 11%; text-align: right" title="Total Cost of Revenue">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--CostOfSupplementsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z2g72jhWdcij" title="Concentration risk, percentage">0.0</span>%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CostOfRevenue_c20250101__20250630__srt--ProductOrServiceAxis__custom--CostOfSupplementsMember_zDISvJacI2ce" style="width: 11%; text-align: right">663</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--CostOfSupplementsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zlKiZolN3kHd" title="Concentration risk, percentage">0.4</span>%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cost for administration of medical procedures</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--CostOfRevenue_c20260101__20260630__srt--ProductOrServiceAxis__custom--CostForAdministrationOfMedicalProceduresMember_zy7iQ6sppmui" style="text-align: right">153,550</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--CostForAdministrationOfMedicalProceduresMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zZMbRhuKhXj9" title="Concentration risk, percentage">49.3</span>%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--CostOfRevenue_d0_c20250101__20250630__srt--ProductOrServiceAxis__custom--CostForAdministrationOfMedicalProceduresMember_zYDQpTFvUmJl" style="text-align: right">70,788</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--CostForAdministrationOfMedicalProceduresMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zwxQmexLpFge" title="Concentration risk, percentage">47.2</span>%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Cost of biologics</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--CostOfRevenue_c20260101__20260630__srt--ProductOrServiceAxis__custom--CostOfBiologicsMember_z16mlobcJG8b" style="border-bottom: Black 1pt solid; text-align: right">157,953</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--CostOfBiologicsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zLbouDbdHQki" title="Concentration risk, percentage">50.7</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--CostOfRevenue_d0_c20250101__20250630__srt--ProductOrServiceAxis__custom--CostOfBiologicsMember_zuNK0pPxSiSf" style="border-bottom: Black 1pt solid; text-align: right">78,484</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--CostOfBiologicsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zllTwlOtWnee" title="Concentration risk, percentage">52.4</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Cost of Revenue</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--CostOfRevenue_c20260101__20260630_zfRvpC9umPd7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total Cost of Revenue">311,503</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20260101__20260630__srt--ProductOrServiceAxis__custom--TotalCostOfRevenueMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zE5MFdFXl8Mb" title="Concentration risk, percentage">100.0</span>%</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--CostOfRevenue_c20250101__20250630_zBuSokyVtQhk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total Cost of Revenue">149,935</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20250101__20250630__srt--ProductOrServiceAxis__custom--TotalCostOfRevenueMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--CostOfRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zq3NxBV20cCb" title="Concentration risk, percentage">100.0</span>%</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 0 0.000 663 0.004 153550 0.493 70788 0.472 157953 0.507 78484 0.524 311503 1.000 149935 1.000 <p id="xdx_84E_eus-gaap--RegulatoryIncomeTaxesPolicy_zAGOD6FXduzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_866_zUpwG1Adbwdh">Income Taxes and Valuation Allowance</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes under ASC 740, “<i>Income Taxes”</i>. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. All of the Company’s deferred tax assets were offset by a full valuation allowance for June 30, 2026 and December 31, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zdXpaqOweaa8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_867_zO4scRdZJcaf">Financial Instruments</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820, <i>“Fair Value Measurements and Disclosures,”</i> defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.6in"> </td> <td style="width: 0.6in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 -</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 -</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 -</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs that are both significant to the fair value measurement and unobservable.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2026. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not have any assets or liabilities measured at fair value on a recurring basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_849_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zuIBNdPrQBPc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86B_zBveoXye9Zte">Related Parties</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows ASC 850-10, <i>“Related Party Disclosures,” </i>for the identification of related parties and disclosure of related party transactions. The Company leases office space from an entity that is controlled by the CEO and Director of the Company. In addition this related party has provided working capital to the Company on the line of credit facility it has extended to the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) principal owners of the Company; c) management of the Company; d) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and e) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Material related party transactions are required to be disclosed in the consolidated financial statements, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a) the nature of the relationship(s) involved; b) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which statements of operation are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c) the dollar amounts of transactions for each of the periods for which statements of operations are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zP5anoww4LUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86C_z7RSUEidaPi6">Commitments and Contingencies</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows ASC 450-20, “<i>Loss Contingencies</i>,” to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zSLUFirPqkle" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_864_zaVTf4o3FBrh">Earnings (loss) per share</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic income (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average common shares outstanding for the period. Diluted income (loss) per share is computed giving effect to all potentially dilutive common shares. Potentially dilutive common shares may consist of incremental shares issuable upon the exercise of stock options and warrants and upon the conversion of notes. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. The number of potentially dilutive common shares (if the preferred shares were converted) for the three and six months ended June 30, 2026 and 2025, are <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260401__20260630_zkuD9oTKjFaj" title="Potentially dilutive common shares"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630_zBx3Y7ztUNba" title="Potentially dilutive common shares"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250401__20250630_zWwT6400TrY7" title="Potentially dilutive common shares"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630_z3CN9fNyVDi4" title="Potentially dilutive common shares">67,000,000</span></span></span></span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 67000000 67000000 67000000 67000000 <p id="xdx_840_eus-gaap--InventoryPolicyTextBlock_z35ghWBFnrNj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86C_zpcViRPBrlPg">Inventory</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are carried at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of applicable variable selling expenses. Management periodically evaluates if a reserve is necessary, and management determined that a reserve was not necessary at June 30, 2026 and December 31, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--InvestmentPolicyTextBlock_zdYn5g2fuYtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_862_zBWq0RfnP9z9">Investments</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 321, <i>“Investments – Equity Securities,”</i> our investment in Cement Factory, LLC is stated at cost, as our investment in this entity constitutes less than 20% in Cement Factory, LLC and does not provide the Company control over this entity. The original agreement entered into was rescinded, and replaced with an agreement to acquire an 18% membership interest in Cement Factory, LLC, allowing the Company to receive an <span id="xdx_908_eus-gaap--InvestmentCompanyTotalReturn_dp_c20260101__20260630__srt--OwnershipAxis__custom--CementFactoryLLCMember_zlOxN0o2fRNa" title="Dividend percentage">18</span>% dividend income from Cement Factory paid annually at the end of each calendar year based on profitability. (See Note 8.)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 0.18 <p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_z6bzTwvfmmFg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_864_zlzwHCRxBI7j">Leases</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, <i>“Leases”</i> Topic 842, which amends the guidance in former ASC Topic 840, Leases (“ASC 840”). The new standard increases transparency and comparability most significantly by requiring the recognition by lessees of right-of-use (“ROU”) assets and lease liabilities on the balance sheet for all leases longer than 12 months. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. For lessees, leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement, over the expected term on a straight-line basis. We determine if an arrangement is a lease at inception. The Company recognizes ROU assets and lease liabilities for leases with terms greater than 12 months or leases that contain a purchase option that is reasonably certain to be exercised. Leases are classified as either finance or operating leases. This classification dictates whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. Operating leases are included in operating lease ROU assets and operating lease liabilities on our consolidated balance sheets. Finance leases are included in finance lease assets, current finance lease liabilities, and long-term finance lease liabilities on our consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s ROU assets and lease liabilities are recognized on the lease commencement date in an amount that represents the present value of future lease payments over the lease term. The Company utilizes its collateralized incremental borrowing rate commensurate to the lease term as the discount rate for its leases unless the Company can specifically determine the lessor’s implicit rate. Certain lease contracts contain non-lease components such as maintenance and utilities. The Company has made a policy election to not separate the lease and non-lease components, and thus recognize a single lease component for all of its right-of-use assets and liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In evaluating contracts to determine if they qualify as a lease, the Company considers factors such as if it has obtained substantially all of the rights to the underlying asset through exclusivity, if the Company can direct the use of the asset by making decisions about how and for what purpose the asset will be used and if the lessor has substantive substitution rights. Furthermore, the Company assesses whether it is reasonably certain to exercise options to extend or terminate a lease considering all relevant factors that create economic incentive to exercise such options, including asset, contract, market, and entity-based factors. These evaluations may require significant judgment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_845_ecustom--LossContingenciesPolicyTextBlock_zSBEeF2dKB3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><span id="xdx_863_zxsUhBiCYwN6">Loss Contingencies</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time the Company may be subject to various legal proceedings and claims that arise in the ordinary course of business. On at least a quarterly basis, consistent with ASC 450-20-50-1C, if the Company determines that there is a reasonable possibility that a material loss may have been incurred, or is reasonably estimable, regardless of whether the Company accrued for such a loss (or any portion of that loss), the Company will confer with its legal counsel, consistent with ASC 450. If the material loss is determinable or reasonably estimable, the Company will record it in its accounts and as a liability on the consolidated balance sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z3mh11FwVdAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_868_zHfLC5dxqMm">Fixed Assets</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows ASC 360, “<i>Property, Plant, and Equipment,”</i> for its fixed assets. Equipment is stated at cost less accumulated depreciation. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets (<span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__srt--RangeAxis__srt--MinimumMember_z9HAsyaqUfCb" title="Estimated useful lives">3</span> to <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__srt--RangeAxis__srt--MaximumMember_z6SawKQq0c7h" title="Estimated useful lives">7</span> years for equipment). Depreciation expense for the three months ended June 30, 2026 and 2025, was $<span id="xdx_906_eus-gaap--Depreciation_c20260401__20260630_zHNbcHWMEA23" title="Depreciation">1,443</span> and $<span id="xdx_90C_eus-gaap--Depreciation_c20250401__20250630_z5GwqoK3ZvQh" title="Depreciation">1,143</span>, respectively, and $<span id="xdx_902_eus-gaap--Depreciation_c20260101__20260630_zAU81hNTO2oe" title="Depreciation">2,695</span> and $<span id="xdx_908_eus-gaap--Depreciation_c20250101__20250630_zIvZf6AaZtp4" title="Depreciation">1,916</span> for the six months ended June 30, 2026 and 2025, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> P3Y P7Y 1443 1143 2695 1916 <p id="xdx_84A_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zSUUhSe7wMEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zM4Wd38VkV6e">Long-lived Assets</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-lived assets such as fixed assets and identifiable intangibles are reviewed for impairment whenever facts and circumstances indicate that the carrying value may not be recoverable. When required impairment losses on assets to be held and used are recognized based on the fair value of the asset. The fair value is determined based on estimates of future cash flows, market value of similar assets, if available, or independent appraisals, if required. If the carrying amount of the long-lived asset is not recoverable from its undiscounted cash flows, an impairment loss is recognized for the difference between the carrying amount and fair value of the asset. When fair values are not available, the Company estimates fair value using the expected future cash flows discounted at a rate commensurate with the risk associated with the recovery of the assets. We did not recognize any impairment losses for any periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zZ6HPeinZh39" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_863_z8g0pES2Oi3l">Segment Reporting</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating segments are components of an enterprise about which separate financial information is available and is evaluated regularly by management, namely the Chief Operating Decision Maker (“CODM”) of an organization, in order to determine operating and resource allocation decisions. By this definition, the Company has identified its Chief Executive Officer as the CODM. The CODM has identified Adia Labs and Adia Med as the Company’s operating segments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z3ugzOEZ80Nf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_862_zXKtyKNYYPGf">Stock-Based Compensation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 718 <i>“Compensation – Stock Compensation,”</i> prescribes accounting and reporting standards for all stock-based payments award to employees, including employee stock options, restricted stock, employee stock purchase plans and stock appreciation rights, may be classified as either equity or liabilities. The Company determines if a present obligation to settle the share-based payment transaction in cash or other assets exists. A present obligation to settle in cash or other assets exists if: (a) the option to settle by issuing equity instruments lacks commercial substance or (b) the present obligation is implied because of an entity’s past practices or stated policies. If a present obligation exists, the transaction should be recognized as a liability; otherwise, the transaction should be recognized as equity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of FASB ASC 505-50 “<i>Equity – Based Payments to Non-Employees</i>.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date. For the three months ended June 30, 2026 and 2025, the Company did <span id="xdx_90E_eus-gaap--ShareBasedCompensation_do_c20260401__20260630_zxgscDZPWee1" title="Share-based compensation"><span id="xdx_90A_eus-gaap--ShareBasedCompensation_do_c20250401__20250630_z6tIQhd8rJMf" title="Share-based compensation">no</span></span>t have any share-based compensation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 0 0 <p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zy2cvv7CCyrd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_867_zKJ6j5tf2wsl">Recently Issued Accounting Pronouncements</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the corporation’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration. For the year ended December 31, 2025, we adopted the ASU 2023-09, <i>“Income Taxes (Topic 740) Improvement to Income Tax Disclosure”</i>, to appropriately reconcile to specific tax rate provisions. As a result, certain prior year amounts have been reclassified for consistency with current year presentation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_80C_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zQLw2oxdiPz2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 4 – <span id="xdx_829_zEgMSPV06J6h">ACCOUNTS RECEIVABLE AND ALLOWANCE FOR CREDIT LOSSES</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable are stated at amortized cost and consist primarily of trade receivables from customers arising from the sale of goods/services in the ordinary course of business. The Company estimates expected credit losses on accounts receivable using relevant available information from internal and external sources, including historical credit loss experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amounts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company's historical credit loss experience on trade receivables, adjusted for current conditions and reasonable and supportable forecasts of future economic conditions, results in an expectation that nonpayment of the amortized cost basis is zero. This assessment considers factors such as the credit quality of customers, short collection periods, low historical default rates, and no material adverse changes expected in relevant economic conditions or customer circumstances.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accordingly, <span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_do_c20260630_z1lMyo3drD0j" title="Allowance for credit losses"><span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_do_c20251231_z3jBEH3hJI3f" title="Allowance for credit losses">no</span></span> allowance for credit losses has been recorded as of June 30, 2026 and December 31, 2025, and <span id="xdx_901_eus-gaap--AccountsReceivableChangeInMethodCreditLossExpenseReversal_do_c20260401__20260630_zBsLN7f0dGdk" title="Credit loss expense"><span id="xdx_908_eus-gaap--ProvisionForDoubtfulAccounts_do_c20260101__20260630_zu1o6NMAcjM7" title="Credit loss expense"><span id="xdx_909_eus-gaap--ProvisionForDoubtfulAccounts_do_c20260401__20260603_z4GHhVn1pWih" title="Credit loss expense">no</span></span></span> credit loss expense related to accounts receivable was recognized during the three and six months ended June 30, 2026 and the year ended December 31, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 0 0 0 0 0 <p id="xdx_809_eus-gaap--InventoryDisclosureTextBlock_zZcHOxaYn0k1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 5 - <span id="xdx_826_zB4AUPHuqFd5">INVENTORY</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventory consists of the following:</p> <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zVIUrK0UYux3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - INVENTORY (Details - Inventory)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B9_zwFQhSkDujJa" style="display: none">Schedule of inventory</span></td><td> </td> <td colspan="3" id="xdx_49A_20260630_zMYGMwYTxt2c" style="text-align: center"> </td><td> </td> <td colspan="3" id="xdx_491_20251231_zELutT12bQn7" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2026</b></p></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, <br/> 2025</td></tr> <tr id="xdx_40F_eus-gaap--InventoryNet_iI_d0_hus-gaap--PublicUtilitiesInventoryAxis__custom--BiologicProductsMember_zpolciBaut" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-bottom: 1pt">Biologic products</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">140,500</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">25,025</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryNet_iI_hus-gaap--PublicUtilitiesInventoryAxis__custom--BiologicsMember_zqrd4D5sGjn1" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Inventory</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">140,500</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">25,025</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A4_z2Iyj9ggl4Vi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zVIUrK0UYux3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - INVENTORY (Details - Inventory)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B9_zwFQhSkDujJa" style="display: none">Schedule of inventory</span></td><td> </td> <td colspan="3" id="xdx_49A_20260630_zMYGMwYTxt2c" style="text-align: center"> </td><td> </td> <td colspan="3" id="xdx_491_20251231_zELutT12bQn7" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2026</b></p></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, <br/> 2025</td></tr> <tr id="xdx_40F_eus-gaap--InventoryNet_iI_d0_hus-gaap--PublicUtilitiesInventoryAxis__custom--BiologicProductsMember_zpolciBaut" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-bottom: 1pt">Biologic products</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">140,500</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">25,025</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryNet_iI_hus-gaap--PublicUtilitiesInventoryAxis__custom--BiologicsMember_zqrd4D5sGjn1" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Inventory</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">140,500</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">25,025</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 140500 25025 140500 25025 <p id="xdx_80E_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z1Gb9jSudyI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 6 – <span id="xdx_823_z0xzC8zrKlw7">FIXED ASSETS, NET</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fixed assets, net, consists of the following:</p> <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_z60FoVi4uLHk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - FIXED ASSETS, NET (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BC_z5hAMYXKyN05" style="display: none">Schedule of fixed assets</span></td><td> </td> <td colspan="3" id="xdx_49C_20260630_zLkSRBtVH4W9" style="text-align: center"> </td><td> </td> <td colspan="3" id="xdx_49B_20251231_z684ZoiwBBj3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2026</b></p></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Furniture and fixtures</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zl1c8ePJBEOc" style="width: 13%; text-align: right" title="Property and equipment, gross">5,332</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zKM4bhSKRu6g" style="width: 13%; text-align: right" title="Property and equipment, gross">5,332</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Machinery and equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_z6AAgTvszSe9" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment, gross">35,193</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_z11taiZQvkeb" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment, gross">29,698</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzpuG_zXONFoK4dXFk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property and equipment, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,525</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,030</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzpuG_zfgcLDOye2Xd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(7,030</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,335</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzpuG_zqjOIXMupov6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Fixed Assets, Net</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">33,495</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">30,695</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zEazEqPIuGbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_z60FoVi4uLHk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - FIXED ASSETS, NET (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BC_z5hAMYXKyN05" style="display: none">Schedule of fixed assets</span></td><td> </td> <td colspan="3" id="xdx_49C_20260630_zLkSRBtVH4W9" style="text-align: center"> </td><td> </td> <td colspan="3" id="xdx_49B_20251231_z684ZoiwBBj3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2026</b></p></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Furniture and fixtures</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zl1c8ePJBEOc" style="width: 13%; text-align: right" title="Property and equipment, gross">5,332</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zKM4bhSKRu6g" style="width: 13%; text-align: right" title="Property and equipment, gross">5,332</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Machinery and equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_z6AAgTvszSe9" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment, gross">35,193</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_z11taiZQvkeb" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment, gross">29,698</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzpuG_zXONFoK4dXFk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property and equipment, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,525</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,030</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzpuG_zfgcLDOye2Xd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(7,030</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,335</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzpuG_zqjOIXMupov6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Fixed Assets, Net</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">33,495</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">30,695</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 5332 5332 35193 29698 40525 35030 7030 4335 33495 30695 <p id="xdx_809_eus-gaap--BusinessCombinationDisclosureTextBlock_zPdiH6NjnNE" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 7 – <span id="xdx_82E_zXlHS23h3EJb">ACQUISITION OF NEW BUSINESS</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 11, 2024, the Company acquired a <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20240711__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BioleteMember_zche2mr3ZSDh" title="Membership interest owned">100</span>% membership interest in Biolete, LLC, a company involved in the development of a protein coffee with mushroom extracts. This acquisition was treated as an asset acquisition valued at $<span id="xdx_903_eus-gaap--BusinessCombinationConsiderationTransferred1_c20240710__20240711__us-gaap--BusinessAcquisitionAxis__custom--BioleteLLCMember_ze97m3fgdlvl" title="Acquisition value">72,000</span>, in which the Company received $<span id="xdx_903_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iI_c20240711__us-gaap--BusinessAcquisitionAxis__custom--BioleteLLCMember_zeyu0okeT3Ih" title="Business acquisition, inventory acquired">70,000</span> in inventory, and a trademark on the product valued at $<span id="xdx_90A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_iI_c20240711__us-gaap--BusinessAcquisitionAxis__custom--BioleteLLCMember_z6dRSPxQkux1" title="Business acquisition, trademark acquired">2,000</span>. Subsequently, the Company invested additional monies to acquire additional trademarks. Consideration provided for this acquisition was the issuance of <span id="xdx_908_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20240710__20240711__us-gaap--BusinessAcquisitionAxis__custom--BioleteLLCMember_z7ASmdGUXZrk" title="Business acquisition, shares issued">1,750,000</span> shares of the Company’s Series C Preferred Stock. Going forward from the acquisition date the revenue and expenses associated with the Biolete brand have been consolidated with the Company’s reported financials.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2025, the Company sold the inventory on hand and the associated trademarks of the Biolete brand to Cement Factory, in which the Company continues to hold an <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20250930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BioleteMember_zUTYVU8Ozr5i" title="Membership interest owned">18</span>% membership interest. The Company transferred the inventory at cost totaling $<span id="xdx_901_eus-gaap--AccountsReceivableNetNoncurrent_iI_c20250930__srt--CounterpartyNameAxis__custom--CementFactoryMember__us-gaap--DisposalGroupClassificationAxis__custom--BioleteInventoryMember_ziusrd1v7dza" title="Account receivable, noncurrent">66,192</span>, all of the trademarks on the Biolete brands net of amortization totaling $<span id="xdx_904_eus-gaap--AccountsReceivableNetNoncurrent_iI_c20250930__srt--CounterpartyNameAxis__custom--CementFactoryMember__us-gaap--DisposalGroupClassificationAxis__custom--BioleteTrademarksMember_zq2fnxl2wbQ4" title="Account receivable, noncurrent">5,463</span>, and the cost of the investment into the Biolete website totaling $<span id="xdx_90E_eus-gaap--AccountsReceivableNetNoncurrent_iI_c20250930__srt--CounterpartyNameAxis__custom--CementFactoryMember__us-gaap--DisposalGroupClassificationAxis__custom--BioleteWebsiteMember_ziGAxkMIbBN9" title="Account receivable, noncurrent">706</span>, as a result the Company has recorded a receivable in the amount of $<span id="xdx_908_eus-gaap--AccountsReceivableNetNoncurrent_iI_c20250930__srt--CounterpartyNameAxis__custom--CementFactoryMember_z94cbOUUsxZb" title="Account receivable, noncurrent">72,361</span> on the transfer date. During the six months ended June 30, 2026 and the year ended December 31, 2025, Cement Factory made payments totaling $<span id="xdx_909_eus-gaap--ProceedsFromDivestitureOfBusinesses_c20260101__20260630__us-gaap--LongLivedAssetsHeldForSaleByAssetTypeAxis__custom--CementFactoryMember_zUjXZabHedAa" title="Proceeds from sale of business">376</span> and $<span id="xdx_90F_eus-gaap--ProceedsFromDivestitureOfBusinesses_c20250101__20251231__us-gaap--LongLivedAssetsHeldForSaleByAssetTypeAxis__custom--CementFactoryMember_zQwHPsPGqPFe" title="Proceeds from sale of business">254</span>, respectively, toward this receivable, resulting in an amount due of $<span id="xdx_908_eus-gaap--AccountsReceivableNetNoncurrent_iI_c20260630__srt--CounterpartyNameAxis__custom--CementFactoryMember_zmehD3VmCSTg" title="Account receivable, noncurrent"><span id="xdx_90D_eus-gaap--AccountsReceivableNetNoncurrent_iI_c20251231__srt--CounterpartyNameAxis__custom--CementFactoryMember_zT0IPwikEHx8" title="Account receivable, noncurrent">71,731</span></span> at June 30, 2026 and December 31, 2025, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> 1 72000 70000 2000 1750000 0.18 66192 5463 706 72361 376 254 71731 71731 <p id="xdx_801_eus-gaap--InvestmentTextBlock_z5sOnEdlvz36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 8 – <span id="xdx_82B_z2choWeTmyn7">INVESTMENT IN NON-CONSOLIDATED BUSINESS ENTITY</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 29, 2024, the Company acquired a 7% membership interest in Cement Factory Nutrition, a health and wellness company. Consideration provided for this acquisition was the issuance of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20240728__20240729__us-gaap--BusinessAcquisitionAxis__custom--CementFactoryNutritionMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zpOzb8NzkWae" title="Stock issued for acquisition, shares">1,875,000</span> shares of the Company’s Series C Preferred Stock. On September 24, 2024, the agreement for the acquisition of the membership interest in Cement Factory Nutrition was rescinded and replaced with the acquisition of <span id="xdx_902_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20240924__srt--OwnershipAxis__custom--CementFactoryLLCMember_zcYYIP7S4L9e" title="Ownership interest (as a percent)">18</span>% membership interest in Cement Factory, LLC. Going forward, the Company will receive <span id="xdx_90F_eus-gaap--InvestmentCompanyTotalReturn_dp_c20240928__20240929__srt--OwnershipAxis__custom--CementFactoryLLCMember_zM3tmJK49Jy6" title="Dividend percentage">18</span>% dividend income from Cement Factory paid annually at the end of each calendar year based on profitability. Our investment in Cement Factory, LLC is stated at cost, as our investment in this entity constitutes less than 20% in Cement Factory, LLC and does not provide the Company control over this entity. To date, Cement Factory has not generated a profit; as a result, for the three and six months ended June 30, 2026 and 2025, the Company did <span id="xdx_905_eus-gaap--DividendIncomeOperating_do_c20260401__20260630_zd63AVr6oOc" title="Dividend income"><span id="xdx_903_eus-gaap--DividendIncomeOperating_do_c20260101__20260630_z7cVCb74ROz5" title="Dividend income"><span id="xdx_907_eus-gaap--DividendIncomeOperating_do_c20250401__20250630_zkT9OyFLIgR3" title="Dividend income"><span id="xdx_905_eus-gaap--DividendIncomeOperating_do_c20250101__20250630_z3g3AzPQphQ5" title="Dividend income">no</span></span></span></span>t receive any dividend income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 1875000 0.18 0.18 0 0 0 0 <p id="xdx_80A_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zrmIjqdT0hYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 9 – <span id="xdx_822_zWK5epizyKz">RELATED PARTY TRANSACTIONS</span></span></b> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 30, 2024, the Company entered into an agreement with the Chief Executive Officer of the Company for an unsecured $500,000 line of credit facility. Total credit was increased to $750,000 with the addition of another $250,000 line of credit facility on June 12, 2025, and an additional $250,000 on May 12, 2026, bearing the same terms as the original line of credit. The total line of credit available from the Chief Executive Officer is currently $<span id="xdx_907_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20260630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zGqfyhX7c4nd" title="Line of credit maximum borrowing capacity">1,000,000</span>. The line of credit bears interest of <span id="xdx_905_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_dp_c20260101__20260630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zrytg8Ul4cR5" title="Line of credit interest rate">6</span>% per annum calculated on a daily basis, and there is no stated maturity date. The entire unpaid principal balance plus any accrued but unpaid interest shall be due and payable twelve months from the date of receipt of demand of payment by the lender. During the year ended December 31, 2025, the Company received advances of $<span id="xdx_904_eus-gaap--ProceedsFromLinesOfCredit_c20250101__20251231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zIPtqhgwcW16" title="Proceeds from line of credit">231,471</span> and during the six months ended June 30, 2026, the Company received advances of $<span id="xdx_902_eus-gaap--ProceedsFromLinesOfCredit_c20260101__20260630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zsQOQZ1hXYi2" title="Proceeds from line of credit">362,812</span> and repaid a total of $<span id="xdx_90B_eus-gaap--RepaymentsOfLinesOfCredit_c20260101__20260630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zuwaL5NCoWu1" title="Repayment of line of credit">127,500</span>. At June 30, 2026 and December 31, 2025, the total outstanding principal balance on this line of credit facility was $<span id="xdx_909_eus-gaap--LineOfCredit_iI_c20260630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zTmL4vntZLsf" title="Line of credit amount outstanding">835,312</span> and $<span id="xdx_90A_eus-gaap--LineOfCredit_iI_c20251231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z7CFnZAqCFFf" title="Line of credit amount outstanding">600,000</span>, respectively. For the three months ended June 30, 2026 and 2025, interest expense was $<span id="xdx_908_eus-gaap--InterestExpenseDebt_c20260401__20260630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--LineOfCreditFacilityAxis__custom--CEOCreditLineMember_z39556vb4Ibi" title="Interest expense">11,786</span> and $<span id="xdx_907_eus-gaap--InterestExpenseDebt_c20250401__20250630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--LineOfCreditFacilityAxis__custom--CEOCreditLineMember_z5039VErClNc" title="Interest expense">7,410</span>, respectively, and for the six months ended June 30, 2026 and 2025, interest expense was $<span id="xdx_90A_eus-gaap--InterestExpenseDebt_c20260101__20260630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--LineOfCreditFacilityAxis__custom--CEOCreditLineMember_z3bZZlvnjUyd" title="Interest expense">22,766</span> and $<span id="xdx_90F_eus-gaap--InterestExpenseDebt_c20250101__20250630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--LineOfCreditFacilityAxis__custom--CEOCreditLineMember_zTXw5ebVgNJ9" title="Interest expense">13,086</span>,  respectively, and total accrued interest at June 30, 2026 and December 31, 2025, was $<span id="xdx_908_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--LineOfCreditFacilityAxis__custom--CEOCreditLineMember_zR5J6SS0yOCa" title="Accrued interest">60,681</span> and $<span id="xdx_904_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20251231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--LineOfCreditFacilityAxis__custom--CEOCreditLineMember_zLFpfTO2QBn1" title="Accrued interest">37,915</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The above amounts and terms of the transactions are not necessarily typical of agreements entered into by third parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 1000000 0.06 231471 362812 127500 835312 600000 11786 7410 22766 13086 60681 37915 <p id="xdx_807_ecustom--LoanToClinicsDisclosureTextBlock_znfK0jysVk6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 10 –<span id="xdx_82B_zK99vDEiT8Fe"> LOANS TO CLINICS</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 15, 2025, the Company provided a start-up loan to Aspire Regenerative Therapy in the amount of $<span id="xdx_90D_eus-gaap--NotesAndLoansReceivableNetNoncurrent_iI_c20250715__srt--CounterpartyNameAxis__custom--AspireRegenerativeTherapyMember_zFMqCUAhcajd" title="Loan receivable">25,000</span>. The terms of the loan are for the principal to be repaid in 5 years at 6% interest per annum. The Company has agreed to receive interest only payments for the first year. At June 30, 2026 and December 31, 2025, the total outstanding principal balance on this loan was $<span id="xdx_90C_eus-gaap--NotesAndLoansReceivableNetNoncurrent_iI_c20251231__srt--CounterpartyNameAxis__custom--AspireRegenerativeTherapyMember_z3K7gBeeGGhh" title="Loan receivable"><span id="xdx_903_eus-gaap--NotesAndLoansReceivableNetNoncurrent_iI_c20250630__srt--CounterpartyNameAxis__custom--AspireRegenerativeTherapyMember_zw2AWj9szytc" title="Loan receivable">25,000</span></span>. For the three months ended June 30, 2026 and 2025, interest income was $<span id="xdx_901_eus-gaap--InvestmentIncomeInterest_c20260401__20260630__srt--CounterpartyNameAxis__custom--AspireRegenerativeTherapyMember_zlaNH6bbbbAe" title="Interest income">375</span> and $<span id="xdx_90A_eus-gaap--InvestmentIncomeInterest_c20250401__20250630__srt--CounterpartyNameAxis__custom--AspireRegenerativeTherapyMember_zmkREbzNiQi6" title="Interest income">0</span>, respectively, and $<span id="xdx_905_eus-gaap--InvestmentIncomeInterest_c20260101__20260630__srt--CounterpartyNameAxis__custom--AspireRegenerativeTherapyMember_zyeXj7p9RXod" title="Interest income">750</span> and $<span id="xdx_90B_eus-gaap--InvestmentIncomeInterest_c20250101__20250630__srt--CounterpartyNameAxis__custom--AspireRegenerativeTherapyMember_zjyBpLAMI0Q6" title="Interest income">0</span> for the six months ended June 30, 2026 and 2025, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 6, 2026, the Company paid the IRB fees on behalf of Greater Atlanta Integrative Pediatirics (“GAIP”) required to conduct a clinical study for autism. The payment of the fees are treated as a loan to GAIP in the amount of $<span id="xdx_904_eus-gaap--NotesAndLoansReceivableNetNoncurrent_iI_c20260406__srt--CounterpartyNameAxis__custom--GAIPMember_zQyqN3MHWKXk" title="Loan receivable">5,300</span>. GAIP will pay the Company an additional $100 per vial of biologics order from the Company until the balance of the loan is repaid. For the three and six months ended June 30, 2026 and 2025, there were <span id="xdx_902_eus-gaap--ProceedsFromSaleAndCollectionOfNotesReceivable_do_c20260401__20260630__srt--CounterpartyNameAxis__custom--GAIPMember_zzWib9I14Oe9" title="Proceeds from note receivable"><span id="xdx_901_eus-gaap--ProceedsFromSaleAndCollectionOfNotesReceivable_do_c20260101__20260630__srt--CounterpartyNameAxis__custom--GAIPMember_zjXfkEo38Uyk" title="Proceeds from note receivable">no</span></span> repayments towards this loan, and at June 30, 2026, the balance of the loan is $<span id="xdx_909_eus-gaap--NotesAndLoansReceivableNetNoncurrent_iI_c20260630__srt--CounterpartyNameAxis__custom--GAIPMember_zN902I7XtjB2" title="Loan receivable">5,300</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 25000 25000 25000 375 0 750 0 5300 0 0 5300 <p id="xdx_80E_ecustom--LesseeOperatingAndFinanceLeasesTextBlock_zbkqFNJZCU57" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 11 - <span id="xdx_822_zafKh28h4AAc">LEASES</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has an operating lease for office space and a finance lease for equipment. Leasing arrangements require fixed payments and also include an amount that is probable and will be owed under residual value guarantees, if applicable. Lease payments also include payments related to purchase or termination options when the lessee is reasonably certain to exercise the option or is reasonably certain not to exercise the option, respectively. The Company’s lease agreements do not contain any material restrictive covenants. The leases have remaining terms of <span id="xdx_909_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20260630__srt--RangeAxis__srt--MinimumMember_zT1QM1gfvIbf" title="Leases remaining terms">3</span> to <span id="xdx_90E_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20260630__srt--RangeAxis__srt--MaximumMember_zt9ojw0XKsxc" title="Leases remaining terms">5</span> years. The Company executed a finance lease during the year ended December 31, 2024, the lease period commenced January 1, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s right-of-use assets and lease liabilities and other disclosures at June 30, 2026 and at December 31, 2025, are as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--LeaseCostTableTextBlock_zxQ03HOLqqH3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - LEASES (Details - Right-Of-Use Assets and Lease Liabilities)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B3_zM2rKaybS7Nc" style="display: none">Schedule of right-of-use assets and lease liabilities</span></td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating Lease</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Finance Lease</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 56%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use assets obtained in exchange for new lease liabilities</span></td> <td style="width: 2%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20260101__20260630_zyvJanU0fgg1" title="Right-of-use assets obtained in exchange for new lease liabilities, operating lease"><span id="xdx_905_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20250101__20251231_zblHbFDZw6Wa" title="Right-of-use assets obtained in exchange for new lease liabilities, operating lease">168,833</span></span></span></td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_c20260101__20260630_zrcyLwV5nebj" title="Right-of-use assets obtained in exchange for new lease liabilities, finance lease"><span id="xdx_904_eus-gaap--RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_c20250101__20251231_zFetm5MdWzad" title="Right-of-use assets obtained in exchange for new lease liabilities, finance lease">130,294</span></span></span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average remaining lease term</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260630_zS5hqBmWTr6g" title="Weighted-average remaining lease term, operating lease"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_zHgNrkjR66e8" title="Weighted-average remaining lease term, operating lease">1.4</span></span> years</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260630_ze0WWmm495ki" title="Weighted-average remaining lease term, finance lease"><span id="xdx_908_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_z5vFqw2xWNAg" title="Weighted-average remaining lease term, finance lease">3.5</span></span> years</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average discount rate</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20260630_z7lxKxj3Gul5" title="Weighted average discount rate, operating lease"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20251231_zPKBo4uRcDwj" title="Weighted average discount rate, operating lease">7.9</span></span>%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20260630_z9hLFwNlGLZc" title="Weighted average discount rate, finance lease"><span id="xdx_902_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20251231_zUSAYtIfs5wg" title="Weighted average discount rate, finance lease">9.9</span></span>%</span></td> <td> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating Lease</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance Lease</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2026</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Dec. 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2026</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Dec. 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%; text-align: left">Right-of-use assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--OperatingLeaseRightOfUseAssetGross_iI_pp0p0_c20260630_zS532tOTIyd2" style="width: 11%; text-align: right" title="Right-of-use assets operating lease">160,447</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--OperatingLeaseRightOfUseAssetGross_c20251231_pp0p0" style="width: 11%; text-align: right" title="Right-of-use assets, operating lease">160,447</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_c20260630_zMOeXGbxHGRb" style="width: 11%; text-align: right" title="Right-of-use assets finance lease">130,294</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_c20251231_zSgVZZAH0r3a" style="width: 11%; text-align: right" title="Right-of-use assets, finance lease">130,294</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--OperatingLeaseRightOfUseAssetAccumulatedAmortization_iI_pp0p0_c20260630_zpcAGins1whj" style="border-bottom: Black 1pt solid; text-align: right" title="Less: amortization operating lease">80,472</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--OperatingLeaseRightOfUseAssetAccumulatedAmortization_c20251231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Less: amortization, operating lease">52,604</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FinanceLeaseRightOfUseAssetAccumulatedAmortization_c20260630_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Less: amortization finance lease">33,839</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--FinanceLeaseRightOfUseAssetAccumulatedAmortization_c20251231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Less: amortization, finance lease">22,123</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Lease assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20260630_z5y4NfwnXUi1" style="border-bottom: Black 2.5pt double; text-align: right" title="Lease assets, net operating lease">79,975</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20251231_zQB1J6yh4dji" style="border-bottom: Black 2.5pt double; text-align: right" title="Lease assets, net operating lease">107,843</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FinanceLeaseRightOfUseAsset_iI_c20260630_zCtM4tqmVLD2" style="border-bottom: Black 2.5pt double; text-align: right" title="Lease assets, net finance lease">96,455</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FinanceLeaseRightOfUseAsset_iI_c20251231_zKasnYYMRHN4" style="border-bottom: Black 2.5pt double; text-align: right" title="Lease assets, net, finance lease">108,171</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lease liabilities, current</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20260630_zL1NCGWE4ZE6" style="text-align: right" title="Lease liabilities, current operating lease">64,743</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20251231_zpZXwNIsuRl1" style="text-align: right" title="Lease liabilities, current operating lease">63,950</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FinanceLeaseLiabilityCurrent_iI_c20260630_zhikXKD8gDD6" style="text-align: right" title="Lease liabilities, current finance lease">26,784</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityCurrent_iI_c20251231_zfRUaXz1r1K2" style="text-align: right" title="Lease liabilities, current finance lease">26,784</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Lease liabilities, long-term</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20260630_zHgL9SHmu129" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liabilities, long-term operating lease">17,267</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20251231_zY7li97lKv4c" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liabilities, long-term operating lease">45,918</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_c20260630_z00BUfU7xiz4" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liabilities, long-term finance lease">49,671</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_c20251231_zrPmdApjxl27" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liabilities, long-term finance lease">61,387</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease obligation</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseLiability_iI_c20260630_zXv9LmMnfVrl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease obligation operating lease">82,010</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLeaseLiability_iI_c20251231_zWTY6oVJX4S2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease obligation operating lease">109,868</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FinanceLeaseLiability_iI_c20260630_zUGt31EGS5Hj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease obligation finance lease">76,455</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FinanceLeaseLiability_iI_c20251231_zcIF6xJiSjE3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease obligation finance lease">88,171</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zwCap20MzvXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future payments of lease liabilities at June 30, 2026 are as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfFutureMinimumOperatingLeaseAndFinanceLeaseTableTextBlock_zcLNDXM24jd9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - LEASES (Details - Future payments of lease liabilities)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BE_zdiaLTtT7thc" style="display: none">Schedule of future payments of lease liabilities</span></td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating Lease</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance Lease</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c20260630_pp0p0" style="width: 13%; text-align: right" title="2026 operating lease">32,054</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_c20260630_pp0p0" style="width: 13%; text-align: right" title="2026 finance lease">13,392</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20260630_pp0p0" style="text-align: right" title="2027 operating lease">54,482</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c20260630_pp0p0" style="text-align: right" title="2027 finance lease">26,784</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_d0_c20260630_zsGh7ZQWJWeg" style="text-align: right" title="2028 operating lease">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20260630_zA4eunsellZ6" style="text-align: right" title="2028 finance lease">26,784</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2029</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_d0_c20260630_zNyEtuxZ6prh" style="text-align: right" title="2029 operating lease">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20260630_zcXX316uO336" style="text-align: right" title="2029 finance lease">26,784</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pp0p0_d0_c20260630_z8x3uIdWGyA8" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter operating lease">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearThree_iI_pp0p0_d0_c20260630_z5227alO076e" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter finance lease">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20260630_zA22cTW77UT1" style="text-align: right" title="Payments due operating lease">86,536</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_c20260630_zftagC1i1KZh" style="text-align: right" title="Payments due finance lease">93,744</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20260630_zdLcRuFf8K4a" style="border-bottom: Black 1pt solid; text-align: right" title="Less interest operating lease">(4,526</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20260630_zVJ81B0C0wVa" style="border-bottom: Black 1pt solid; text-align: right" title="Less interest finance lease">(17,289</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingLeaseLiability_iI_c20260630_zC1pPRldgpSa" style="border-bottom: Black 2.5pt double; text-align: right" title="Total operating lease">82,010</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FinanceLeaseLiability_iI_c20260630_zuC4P2qFiNg5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total finance lease">76,455</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_z6ZL5Gt8xb51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> P3Y P5Y <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--LeaseCostTableTextBlock_zxQ03HOLqqH3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - LEASES (Details - Right-Of-Use Assets and Lease Liabilities)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B3_zM2rKaybS7Nc" style="display: none">Schedule of right-of-use assets and lease liabilities</span></td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating Lease</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Finance Lease</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 56%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use assets obtained in exchange for new lease liabilities</span></td> <td style="width: 2%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20260101__20260630_zyvJanU0fgg1" title="Right-of-use assets obtained in exchange for new lease liabilities, operating lease"><span id="xdx_905_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20250101__20251231_zblHbFDZw6Wa" title="Right-of-use assets obtained in exchange for new lease liabilities, operating lease">168,833</span></span></span></td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_c20260101__20260630_zrcyLwV5nebj" title="Right-of-use assets obtained in exchange for new lease liabilities, finance lease"><span id="xdx_904_eus-gaap--RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_c20250101__20251231_zFetm5MdWzad" title="Right-of-use assets obtained in exchange for new lease liabilities, finance lease">130,294</span></span></span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average remaining lease term</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260630_zS5hqBmWTr6g" title="Weighted-average remaining lease term, operating lease"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_zHgNrkjR66e8" title="Weighted-average remaining lease term, operating lease">1.4</span></span> years</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260630_ze0WWmm495ki" title="Weighted-average remaining lease term, finance lease"><span id="xdx_908_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_z5vFqw2xWNAg" title="Weighted-average remaining lease term, finance lease">3.5</span></span> years</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average discount rate</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20260630_z7lxKxj3Gul5" title="Weighted average discount rate, operating lease"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20251231_zPKBo4uRcDwj" title="Weighted average discount rate, operating lease">7.9</span></span>%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20260630_z9hLFwNlGLZc" title="Weighted average discount rate, finance lease"><span id="xdx_902_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20251231_zUSAYtIfs5wg" title="Weighted average discount rate, finance lease">9.9</span></span>%</span></td> <td> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating Lease</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance Lease</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2026</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Dec. 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2026</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Dec. 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%; text-align: left">Right-of-use assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--OperatingLeaseRightOfUseAssetGross_iI_pp0p0_c20260630_zS532tOTIyd2" style="width: 11%; text-align: right" title="Right-of-use assets operating lease">160,447</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--OperatingLeaseRightOfUseAssetGross_c20251231_pp0p0" style="width: 11%; text-align: right" title="Right-of-use assets, operating lease">160,447</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_c20260630_zMOeXGbxHGRb" style="width: 11%; text-align: right" title="Right-of-use assets finance lease">130,294</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_c20251231_zSgVZZAH0r3a" style="width: 11%; text-align: right" title="Right-of-use assets, finance lease">130,294</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--OperatingLeaseRightOfUseAssetAccumulatedAmortization_iI_pp0p0_c20260630_zpcAGins1whj" style="border-bottom: Black 1pt solid; text-align: right" title="Less: amortization operating lease">80,472</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--OperatingLeaseRightOfUseAssetAccumulatedAmortization_c20251231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Less: amortization, operating lease">52,604</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FinanceLeaseRightOfUseAssetAccumulatedAmortization_c20260630_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Less: amortization finance lease">33,839</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--FinanceLeaseRightOfUseAssetAccumulatedAmortization_c20251231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Less: amortization, finance lease">22,123</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Lease assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20260630_z5y4NfwnXUi1" style="border-bottom: Black 2.5pt double; text-align: right" title="Lease assets, net operating lease">79,975</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20251231_zQB1J6yh4dji" style="border-bottom: Black 2.5pt double; text-align: right" title="Lease assets, net operating lease">107,843</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FinanceLeaseRightOfUseAsset_iI_c20260630_zCtM4tqmVLD2" style="border-bottom: Black 2.5pt double; text-align: right" title="Lease assets, net finance lease">96,455</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FinanceLeaseRightOfUseAsset_iI_c20251231_zKasnYYMRHN4" style="border-bottom: Black 2.5pt double; text-align: right" title="Lease assets, net, finance lease">108,171</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lease liabilities, current</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20260630_zL1NCGWE4ZE6" style="text-align: right" title="Lease liabilities, current operating lease">64,743</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20251231_zpZXwNIsuRl1" style="text-align: right" title="Lease liabilities, current operating lease">63,950</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FinanceLeaseLiabilityCurrent_iI_c20260630_zhikXKD8gDD6" style="text-align: right" title="Lease liabilities, current finance lease">26,784</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityCurrent_iI_c20251231_zfRUaXz1r1K2" style="text-align: right" title="Lease liabilities, current finance lease">26,784</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Lease liabilities, long-term</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20260630_zHgL9SHmu129" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liabilities, long-term operating lease">17,267</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20251231_zY7li97lKv4c" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liabilities, long-term operating lease">45,918</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_c20260630_z00BUfU7xiz4" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liabilities, long-term finance lease">49,671</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_c20251231_zrPmdApjxl27" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liabilities, long-term finance lease">61,387</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease obligation</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseLiability_iI_c20260630_zXv9LmMnfVrl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease obligation operating lease">82,010</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLeaseLiability_iI_c20251231_zWTY6oVJX4S2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease obligation operating lease">109,868</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FinanceLeaseLiability_iI_c20260630_zUGt31EGS5Hj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease obligation finance lease">76,455</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FinanceLeaseLiability_iI_c20251231_zcIF6xJiSjE3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease obligation finance lease">88,171</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 168833 168833 130294 130294 P1Y4M24D P1Y4M24D P3Y6M P3Y6M 0.079 0.079 0.099 0.099 160447 160447 130294 130294 80472 52604 33839 22123 79975 107843 96455 108171 64743 63950 26784 26784 17267 45918 49671 61387 82010 109868 76455 88171 <table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfFutureMinimumOperatingLeaseAndFinanceLeaseTableTextBlock_zcLNDXM24jd9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - LEASES (Details - Future payments of lease liabilities)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BE_zdiaLTtT7thc" style="display: none">Schedule of future payments of lease liabilities</span></td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating Lease</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance Lease</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c20260630_pp0p0" style="width: 13%; text-align: right" title="2026 operating lease">32,054</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_c20260630_pp0p0" style="width: 13%; text-align: right" title="2026 finance lease">13,392</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20260630_pp0p0" style="text-align: right" title="2027 operating lease">54,482</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c20260630_pp0p0" style="text-align: right" title="2027 finance lease">26,784</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_d0_c20260630_zsGh7ZQWJWeg" style="text-align: right" title="2028 operating lease">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20260630_zA4eunsellZ6" style="text-align: right" title="2028 finance lease">26,784</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2029</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_d0_c20260630_zNyEtuxZ6prh" style="text-align: right" title="2029 operating lease">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20260630_zcXX316uO336" style="text-align: right" title="2029 finance lease">26,784</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pp0p0_d0_c20260630_z8x3uIdWGyA8" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter operating lease">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearThree_iI_pp0p0_d0_c20260630_z5227alO076e" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter finance lease">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20260630_zA22cTW77UT1" style="text-align: right" title="Payments due operating lease">86,536</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_c20260630_zftagC1i1KZh" style="text-align: right" title="Payments due finance lease">93,744</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20260630_zdLcRuFf8K4a" style="border-bottom: Black 1pt solid; text-align: right" title="Less interest operating lease">(4,526</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20260630_zVJ81B0C0wVa" style="border-bottom: Black 1pt solid; text-align: right" title="Less interest finance lease">(17,289</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingLeaseLiability_iI_c20260630_zC1pPRldgpSa" style="border-bottom: Black 2.5pt double; text-align: right" title="Total operating lease">82,010</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FinanceLeaseLiability_iI_c20260630_zuC4P2qFiNg5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total finance lease">76,455</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 32054 13392 54482 26784 0 26784 0 26784 0 0 86536 93744 4526 17289 82010 76455 <p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zbACVyaW99Cb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">NOTE 12 – <span id="xdx_82A_zvxOd49NZun">STOCKHOLDERS’ EQUITY</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Common Stock</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember_z8wLKJIPmTRg" title="Common stock, shares authorized">900,000,000</span> authorized common shares with a par value of $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember_zofPyyhMSrl6" title="Common stock par value">0.001</span> per share. Each common share entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has two common stock designations; Class A Common Stock with <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--CommonClassAMember_zOF2AKcnFf9i" title="Common stock, shares authorized">800,000,000</span> shares authorized, and Class B Common Stock with <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--CommonClassBMember_zGzJowuHmgI" title="Common stock, shares authorized">100,000,000</span> shares authorized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Class A Common Stock</span>: Each share of Class A Common Stock shall have, for all purposes, one (1) vote per share. Subject to the preferences applicable to Preferred Stock outstanding at any time, the holders of the shares of Class A Common Stock shall be entitled to receive such dividends and other distributions in cash, property or shares of stock of the Corporation as may be declared thereon by the Board of Directors from time to time out of assets or funds of the Corporation legally available therefrom. The holders of Class A Common Stock issued and outstanding have and possess the right to receive notice of shareholders’ meetings and to vote upon the election of directors or upon any other matter as to which approval of the outstanding shares of Class A Common Stock or approval of the common shareholders is required or requested.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Class B Common Stock</span>: The shares of Class B Common Stock may be issued from time to time in one or more series. The Board of Directors is authorized, by resolution adopted and filed in accordance with law, to provide for the issue of each series of shares of Class B Common Stock; provided, however, that any issuance of shares of Class B Common Stock shall be made only in connection with a special acquisition transaction, as determined by the Board of Directors. Each series of shares of Class B Common Stock: (a) may have such voting powers, full or limited or may be without voting powers; (b) may be subject to redemption at such time or times and at such prices as determined by the Board of Directors; (c) may be entitled to receive dividends (which may be cumulative or non-cumulative) at such rate or rates, on such conditions and at such times, and payable in preference to, or in relation to, the dividends payable on any other class or classes or series of stock; (d) may have such rights upon the dissolution of, or upon any distribution of assets of, the Corporation; (e) may be made convertible into, or exchangeable for, shares of any other class or classes or of any other series of the same or any other class or classes of stock of the Corporation or such other corporation or other entity at such price or prices or at such rates of exchange and with such adjustments; (f) may be entitled to the benefit of a sinking fund to be applied to the purchase or redemption of shares of such series in such amount or amounts; (g) may be entitled to the benefit of conditions and restrictions upon the creation of indebtedness of the Corporation or any subsidiary, upon the issue of any additional shares (including additional shares of such series or of any other series) and upon the payment of dividends or the making of other distributions on, and the purchase, redemption or other acquisition by the Corporation or any subsidiary of, any outstanding shares of the Corporation; and (h) may have such other relative, participating, optional or other special rights, qualifications, limitations or restrictions thereof, in each case as shall be stated in said resolution or resolutions providing for the issue of such shares of Class B Common Stock. Shares of Class B Common Stock of any series that have been redeemed or repurchased by the Corporation (whether through the operation of a sinking fund or otherwise) or that, if convertible or exchangeable, have been converted or exchanged in accordance with their terms shall be retired and have the status of authorized and unissued shares of Class B Common Stock of the same series and may be reissued as a part of the series of which they were originally a part or may, upon the filing of an appropriate certificate with the Secretary of State of the State of Nevada be reissued as part of a new series of shares of Class B Common Stock to be created by resolution or resolutions of the Board of Directors or as part of any other series of shares of Class B Common Stock, all subject to the conditions or restrictions on issuance set forth in the resolution or resolutions adopted by the Board of Directors providing for the issue of any series of shares of Class B Common Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 9, 2024, the Company received an investment on its Reg A registration statement in the amount of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240708__20240709__us-gaap--SubsidiarySaleOfStockAxis__custom--RegulationAFilingMember_zfwzIJxHlRD6" title="Proceeds from issuance of common stock">40,000</span> in investments, offset by $<span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_c20240708__20240709__us-gaap--SubsidiarySaleOfStockAxis__custom--RegulationAFilingMember_zmx5y81jdwA4" title="Offering costs">15,000</span> in offering costs, resulting in subsequent issuance of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240708__20240709__us-gaap--SubsidiarySaleOfStockAxis__custom--RegulationAFilingMember_ztwtreMIEjof" title="Stock issued new, shares">8,000,000</span> shares of the Company’s Class A Common Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 5, 2025, the Company retired <span id="xdx_90A_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_c20250504__20250505__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember_ziBIf1Ikjshg" title="Number of shares retired">15,495,165</span> shares of its Common Stock. Initially, on May 31, 2024, the Company filed a complaint for declaratory relief, seeking an order declaring as void a total of 15,495,165 shares of the Company’s issued and outstanding shares of Common Stock, held by Lotus Fund (“Lotus”) (10,495,165 shares), and Jason S. Coombs (“Coombs”) (5,000,000 shares), as well as the certain issued and outstanding shares of Series A Preferred Shares. Lotus, Coombs and Singhal (collectively the “Claimants”) were issued these shares but the Company deems that they were not properly acquired through any consideration. The lawsuit (Case Number: 2024CA001088, Case Style: ADIA NUTRITION INC -VS- ADIA NUTRITION INC) was filed pursuant to the laws of the State of Florida, and the venue lies in Seminole County. This matter was settled in favor of the Company on May 5, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 6, 2025, the Company received an investment on its Reg A registration statement in the amount of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250605__20250606__us-gaap--SubsidiarySaleOfStockAxis__custom--RegulationAFilingMember_zaaZqF2F1WWc" title="Proceeds from issuance of common stock">38,500</span> in investments, offset by $<span id="xdx_904_eus-gaap--PaymentsOfStockIssuanceCosts_c20250605__20250606__us-gaap--SubsidiarySaleOfStockAxis__custom--RegulationAFilingMember_zIVdkw2Ak56">15,000</span> in offering costs, resulting in shares to be issued of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250605__20250606__us-gaap--SubsidiarySaleOfStockAxis__custom--RegulationAFilingMember_zVJX3rp9fZG4">7,700,000</span> shares of the Company’s Class A Common Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 11, 2025, the Company received an investment on its Reg A registration statement in the amount of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250610__20250611__us-gaap--SubsidiarySaleOfStockAxis__custom--RegulationAFilingMember_zuFtBCyHtb2l" title="Proceeds from issuance of common stock">31,500</span> in investments, offset by $<span id="xdx_904_eus-gaap--PaymentsOfStockIssuanceCosts_c20250610__20250611__us-gaap--SubsidiarySaleOfStockAxis__custom--RegulationAFilingMember_zGqUruWIr6k2">15,000</span> in offering costs, resulting in shares to be issued of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250610__20250611__us-gaap--SubsidiarySaleOfStockAxis__custom--RegulationAFilingMember_z07eXL9gp8ze">6,300,000</span> shares of the Company’s Class A Common Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At June 30, 2026 and December 31, 2025, there were <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--CommonClassAMember_z4VcmnmqlG5d" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--CommonClassAMember_zz03tXC4JKMa" title="Common stock, shares outstanding"><span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--CommonClassAMember_zlrWGiyRuMCa" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--CommonClassAMember_zkHLLQFY3Bq5" title="Common stock, shares outstanding">94,404,696</span></span></span></span> Class A Common Shares issued and outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At June 30, 2026 and December 31, 2025, there were <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_do_c20260630__us-gaap--AwardTypeAxis__us-gaap--CommonClassBMember_zcU3viW6RPl3" title="Common stock, shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_do_c20260630__us-gaap--AwardTypeAxis__us-gaap--CommonClassBMember_zgqm6W4RHbp3" title="Common stock, shares outstanding"><span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_do_c20251231__us-gaap--AwardTypeAxis__us-gaap--CommonClassBMember_zEl3vEh2pZI" title="Common stock, shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_do_c20251231__us-gaap--AwardTypeAxis__us-gaap--CommonClassBMember_zwhTnn3hCrod" title="Common stock, shares outstanding">no</span></span></span></span> Class B Common Shares issued and outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Preferred Stock </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zVN7wyTGUmc5" title="Preferred stock, shares authorized">100,000,000</span> shares of preferred stock authorized, par value $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zSyFaiREECS3" title="Preferred stock par value">.001</span> per share (the “Preferred Stock”), issuable in one or more series; (a) the Company designated one (<span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20260630__us-gaap--AwardTypeAxis__custom--Special2022SeriesAPreferredStockMember_z30T8pq4JtEb" title="Preferred stock, shares authorized">1</span>) share of Preferred Stock as “Special 2022 Series A Preferred Stock” possessing super-voting rights; (b) the Company designated <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zJIGrxJZV2Si" title="Preferred stock, shares authorized">10,000,000</span> shares of Series A Preferred Stock; and (c) the Company designated <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zqWH3cKFqIpk" title="Preferred stock, shares authorized">89,999,999</span> shares of Series C Preferred Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Special 2022 Series A Preferred Stock.</span> The designation of this class of preferred stock shall be “Special 2022 Series A Preferred Stock,” par value $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20260630__us-gaap--AwardTypeAxis__custom--Special2022SeriesAPreferredStockMember_zs55fFwCvlqd" title="Preferred stock par value">.001</span> per share (the “Special 2022 Series A Preferred Stock”). The number of authorized shares of Special 2022 Series A Preferred Stock is one (1). (A) Voting Rights. Except as otherwise required by law, the holder of the share of Special 2022 Series A Preferred Stock shall have the following rights: (1) Number of Votes; Voting with Common Stock. Except as provided by Nevada statutes or elsewhere herein, the holder of the Special 2022 Series A Preferred Stock shall vote together with the holders of Preferred Stock (including on an as converted basis), and Common Stock, of the Corporation as a single class. The holder of the share of Special 2022 Series A Preferred Stock is entitled to 60% of all votes (including, but not limited to, Common Stock, and Preferred Stock (including on an as converted basis) entitled to vote at each meeting of shareholders of the Corporation (and written actions of shareholders in lieu of meetings) with respect to any and all matters presented to the shareholders of the Corporation for their action or consideration. The share of Special 2022 Series A Preferred Stock shall not be divided into fractional shares. (2) Adverse Effects. The Corporation shall not amend, alter, or repeal the preferences, rights, powers or other terms of the Special 2022 Series A Preferred Stock so as to affect adversely the Special 2022 Series A Preferred Stock, or the holder thereof, without the written consent or affirmative vote of the holder of the Special 2022 Series A Preferred Stock given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class. (B) Conversion. The share of the Special 2022 Series A Preferred Stock shall convert into common shares at a conversion rate of 1 preferred to 60,000,000 common shares. The holder of the Special 2022 Series A Preferred stock can affect the conversion at any time. The conversion into common is a right and is not required. (C) Dividends; Liquidation. The shares of Special 2022 Series A Preferred Stock shall not be entitled to any dividends in respect thereof and shall not participate in any proceeds available to the Corporation’s shareholders upon the liquidation, dissolution or winding up of the Corporation. (D) No Impairment. The Corporation shall not intentionally take any action which would impair the rights and privileges of the Special 2022 Series A Preferred Stock set forth herein or the rights of the holder thereof. The Corporation will not, by amendment of its articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Corporation, but will, at all times, in good faith assist in the carrying out of all the provisions herein and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the holder of the Special 2022 Series A Preferred Stock against impairment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Series A Preferred Stock</span>. The designation of this class of preferred stock shall be “Series A Preferred Stock,” par value $<span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_dxL_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zrlQwN4jxny9" title="Preferred stock par value::XDX::0.001"><span style="-sec-ix-hidden: xdx2ixbrl1313">.001</span></span> per share (the “Series A Preferred Stock”). The number of authorized shares of Series A Preferred Stock is ten million (<span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zN5mSuDxKrN5" title="Preferred stock, shares authorized">10,000,000</span>). Each share of Series A Preferred Stock shall entitle the holder to five (5) votes on any matter submitted to the shareholders of the Corporation for their vote, waiver, release or other action, to be considered in connection with the establishment of a quorum, except as may otherwise be expressly required by law or by the applicable stock exchange rules. The holders of Series A Preferred Stock shall vote together with the shares of Common Stock as one class. (c) Liquidation Rights. Upon the dissolution, liquidation or winding up of the Corporation, whether voluntary or involuntary, the holders of the then-outstanding shares of Series A Preferred Stock shall be entitled to receive out of the assets of the Corporation the sum of $.001 per share (the “Liquidation Rate”) before any payment or distribution shall be made on any other class of capital stock of the Corporation ranking junior to the Series A Preferred Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Series C Preferred Stock</span>. The designation of this class of preferred stock shall be “Series C Preferred Stock,” par value $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_dxL_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zT0AcTKNqGni" title="Preferred stock par value::XDX::0.001"><span style="-sec-ix-hidden: xdx2ixbrl1317">.001</span></span> per share (the “Series C Preferred Stock”). The number of authorized shares of Series C Preferred Stock is eighty-nine million, nine hundred ninety-nine thousand, nine hundred and ninety nine (<span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zAcduHD9KYmb" title="Preferred stock, shares authorized">89,999,999</span>). Each share of Series C Preferred Stock shall entitle the holder to one (1) vote on any matter submitted to the shareholders of the Corporation for their vote, waiver, release or other action, to be considered in connection with the establishment of a quorum, except as may otherwise be expressly required by law or by the applicable stock exchange rules. The holders of Series C Preferred Stock shall vote together with the shares of Common Stock as one class.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liquidation Rights - Upon the dissolution, liquidation or winding up of the Corporation, whether voluntary or involuntary, the holders of the then-outstanding shares of Series C Preferred Stock shall be treated <i>pari passu</i> with the Company’s common stock, except that the payment on each share of the Company’s common stock multiplied by the Conversion Rate. Conversion Rate – Each share of Series C Preferred Stock shall be convertible into four (4) shares of the Company’s common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 11, 2024, the Company acquired a 100% membership interest in Biolete, LLC; consideration provided for this acquisition was the issuance of <span id="xdx_90E_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20240710__20240711__us-gaap--BusinessAcquisitionAxis__custom--BioleteLLCMember_zxT4aJzuYg31" title="Business acquisition, shares issued">1,750,000</span> shares of the Company’s Series C Preferred Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 29, 2024, the Company acquired a 7% membership interest in Cement Factory Nutrition; consideration provided for this acquisition was the issuance of <span id="xdx_90B_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20240728__20240729__us-gaap--BusinessAcquisitionAxis__custom--CementFactoryNutritionMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zOROOOp13t9b" title="Business acquisition, shares issued">1,875,000</span> shares of the Company’s Series C Preferred Stock. On September 24, 2024, the acquisition of the 7% interest in Cement Factory Nutrition was rescinded and these shares were returned and a new agreement was made to acquire and 18% membership interest in Cement Factory, LLC; consideration provided for this acquisition was the reservation of 1,875,000 shares of the Company’s Series C Preferred Stock to be issued at a future date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 19, 2024, the Company appointed Monica Sher, MD as a Director of Company. The Company will issue <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20240818__20240819__us-gaap--NonmonetaryTransactionTypeAxis__custom--SharesToBeIssuedMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--MonicaSherMember_zrGo0j0v5xS5" title="Shares issued for compensation, shares">250,000</span> shares of its Series C Preferred Stock at a future date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 10, 2024, the Company appointed Richard Edwards, DO as a Director of Company. The Company will issue <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20240909__20240910__us-gaap--NonmonetaryTransactionTypeAxis__custom--SharesToBeIssuedMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--RichardEdwardsMember_zctUZuqoTW8f" title="Shares issued for compensation, shares">250,000</span> shares of its Series C Preferred Stock at a future date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 23, 2024, the Company appointed Kalpesh Barot, MD as a Director of Company. The Company will issue <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20240922__20240923__us-gaap--NonmonetaryTransactionTypeAxis__custom--SharesToBeIssuedMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--KalpeshBarotMember_zgGKyvkHsOA3" title="Shares issued for compensation, shares">250,000</span> shares of its Series C Preferred Stock at a future date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 5, 2025, the Company retired and declared void <span id="xdx_90D_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_c20250504__20250505__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxLiOozwhHSj" title="Number of shares retired">10,000,000</span> shares of the Company Series A Preferred Shares. Initially, on May 31, 2024, the Company filed a complaint for declaratory relief, seeking an order declaring as void certain shares of the Company’s issued and outstanding shares of Common Stock. In addition, the lawsuit sought an order declaring as void a total of <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_c20250505__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcLy8bBbE65g" title="Preferred stock, shares issued">10,000,000</span> shares of the Company’s issued and outstanding shares of Series A Preferred Shares, held by Shelly Singhal (“Singhal”). The lawsuit (Case Number: 2024CA001088, Case Style: ADIA NUTRITION INC -VS- ADIA NUTRITION INC) was filed pursuant to the laws of the State of Florida, and the venue lies in Seminole County. This matter was settled in favor of the Company on May 5, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 13, 2025, the Company appointed Dr. Evan Thomas, MD, PhD. as an Independent Medical Director for the Company’s medical division, Adia Med. The Company will issue <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20251012__20251013__us-gaap--NonmonetaryTransactionTypeAxis__custom--SharesToBeIssuedMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--EvanThomasMember_zyWqoTiZbiD7" title="Shares issued for compensation, shares">250,000</span> shares of its Series C Preferred Stock at a future date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the year ended December 31, 2025, per their employment agreements (fully ratified in 2026), two officers of the Company were entitled to the option to purchase a total of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--CounterpartyNameAxis__custom--TwoOfficersMember_zFehVw99cJZf" title="Shares granted during period, shares">15,000,000</span> shares of the Company’s Series C Preferred Stock, however, the Company is obligated to issue these shares at some point in the future, regardless if the options are exercised by the Company or not.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At June 30, 2026 and December 31, 2025, there is one (<span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_c20260630__us-gaap--AwardTypeAxis__custom--Special2022SeriesAPreferredStockMember_zaN0kvhbHam3" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_c20260630__us-gaap--AwardTypeAxis__custom--Special2022SeriesAPreferredStockMember_zLK6o3eMSf92" title="Preferred stock, shares outstanding"><span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_c20251231__us-gaap--AwardTypeAxis__custom--Special2022SeriesAPreferredStockMember_znNCK5Xelyj1" title="Preferred stock, shares issued"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--Special2022SeriesAPreferredStockMember_z5gLbhbcKwj3" title="Preferred stock, shares outstanding">1</span></span></span></span>) share of Special 2022 Series A Preferred issued and outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At June 30, 2026 and December 31, 2025, there are <span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_dxL_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTCxMrLZZP06" title="Preferred stock, shares issued::XDX::0"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_dxL_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zstn3snq6sE8" title="Preferred stock, shares outstanding::XDX::0"><span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_dxL_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z9QwpXvupZig" title="Preferred stock, shares issued::XDX::0"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_dxL_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zc8HJrVy6ek7" title="Preferred stock, shares outstanding::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl1351"><span style="-sec-ix-hidden: xdx2ixbrl1353"><span style="-sec-ix-hidden: xdx2ixbrl1355"><span style="-sec-ix-hidden: xdx2ixbrl1357">zero</span></span></span></span></span></span></span></span> shares of Series A Preferred issued and outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At June 30, 2026 and December 31, 2025, there are <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_znCLRtspdsY1" title="Preferred stock, shares issued"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_ztW0WBLEfJd8" title="Preferred stock, shares outstanding"><span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z8cTlJ7Ugzs9" title="Preferred stock, shares issued"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zaUzT3NHrmL9" title="Preferred stock, shares outstanding">1,750,000</span></span></span></span> shares of Series C Preferred issued and outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 900000000 0.001 800000000 100000000 40000 15000 8000000 15495165 38500 15000 7700000 31500 15000 6300000 94404696 94404696 94404696 94404696 0 0 0 0 100000000 0.001 1 10000000 89999999 0.001 10000000 89999999 1750000 1875000 250000 250000 250000 10000000 10000000 250000 15000000 1 1 1 1 1750000 1750000 1750000 1750000 <p id="xdx_802_eus-gaap--SegmentReportingDisclosureTextBlock_zfuiTt1Xlxq1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 13 – <span id="xdx_826_zcYorlXwOBuh">SEGMENT REPORTING</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2025, the Company had <span id="xdx_902_eus-gaap--NumberOfOperatingSegments_dxL_uInteger_c20250101__20251231_zJIUtmaRLSbe" title="Number of operating segment::XDX::3"><span id="xdx_909_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20250101__20251231_zd9QI4UzyAU9" title="Number of reportable segment::XDX::3"><span style="-sec-ix-hidden: xdx2ixbrl1369"><span style="-sec-ix-hidden: xdx2ixbrl1371">three</span></span></span></span> operating segments: (1) Biolete, (2) Adia Med, and (3) Adia Labs. On September 30, 2025, the Company sold its rights to the Biolete trademarks and all associated assets to Cement Factory, and as a result for the six months ended June 30, 2026, the Company had <span id="xdx_90E_eus-gaap--NumberOfOperatingSegments_dxL_uInteger_c20260101__20260630_ztLTbOleQ8G1" title="Number of operating segment::XDX::2"><span id="xdx_902_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20260101__20260630_zRYlLIAYtrhl" title="Number of reportable segment::XDX::2"><span style="-sec-ix-hidden: xdx2ixbrl1373"><span style="-sec-ix-hidden: xdx2ixbrl1375">two</span></span></span></span> operating segments: (1) Adia Med, and (2) Adia Labs.</p> <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_zA1s5dhH6u9a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details - Segment assets)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B5_zMUnxF0UrUr6" style="display: none">Schedule of segment of assets</span></td><td> </td> <td colspan="3" id="xdx_494_20260630_zjQNHwmjPsYa" style="text-align: center"> </td><td> </td> <td colspan="3" id="xdx_49C_20251231_zXEIjF9bBkVk" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2026</b></p></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2025</td></tr> <tr id="xdx_40E_eus-gaap--Assets_iI_d0_hsrt--ProductOrServiceAxis__custom--AdiaMedAssetsMember_zSYyEE8DRjsg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left">Adia Med assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">284,709</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">261,208</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--Assets_iI_d0_hsrt--ProductOrServiceAxis__custom--AdiaLabsAssetsMember_z8Dnd0sTY8zl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Adia Labs assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">305,625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,025</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--Assets_iI_d0_hsrt--ProductOrServiceAxis__custom--UnallocatedCorporateAssetsMember_z7sSjdf2vePl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Unallocated corporate assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">153,720</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">308,593</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Assets_iI_d0_zLb2kYKumu8c" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">744,054</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">594,826</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8AA_ziVlAeCjxJO7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The CODM reviews performance based on gross profit (sales less cost of products or services sold), operating profit, and net income (loss). Profitability is important to the Company’s ability to grow and expand operations. The Company does not have any operations or sources of revenue outside of the United States. Corporate overhead is not allocated to each segment unless the cost is specifically incurred to support the single segment. This provides the CODM with segment specific costs and profits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company chooses to disclose the following in its segment reporting requirements for the six months ended June 30, 2026:</p> <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zo3W6v5EC8Ej" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details - Segment reporting)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B4_zXkg9QgWjz67" style="display: none">Schedule of segment reporting</span></td><td> </td> <td colspan="3" id="xdx_499_20260101__20260630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zmOAw8RsBmT" style="text-align: center"> </td><td> </td> <td colspan="3" id="xdx_49B_20260101__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--BioleteMember_ziJkSeZrOBU8" style="text-align: center"> </td><td> </td> <td colspan="3" id="xdx_493_20260101__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--AdiaMedMember_z0fYqv9U5LG5" style="text-align: center"> </td><td> </td> <td colspan="3" id="xdx_498_20260101__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--AdiaLabsMember_zXLKdK1mykB4" style="text-align: center"> </td><td> </td> <td colspan="3" id="xdx_494_20260101__20260630_zECXRIfKAg37" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic">For the six months ended June 30, 2026</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Unallocated</td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Corporate</td><td> </td> <td colspan="3" style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">ADIA</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">ADIA</td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Overhead</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Biolete</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Med</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Labs</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Totals</td></tr> <tr id="xdx_40D_eus-gaap--SegmentReportingInformationRevenueAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Segment Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_d0_hsrt--ProductOrServiceAxis__custom--MedicalProceduresMember_zdnHoW4XXyp3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 30%; text-align: left">Medical procedures</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">434,670</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">434,670</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--Revenues_d0_hsrt--ProductOrServiceAxis__custom--SalesOfBiologicsNetOfDiscountsAndRefundsMember_zI0zZgXcOk0i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Sales of biologics, net of discounts and refunds</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">221,525</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">221,525</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--Revenues_d0_hsrt--ProductOrServiceAxis__custom--ShippingAndDeliveryMember_z3a82x3uzCb2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Shipping and delivery</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,465</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,465</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--Revenues_d0_zg6Ubsdj4cvb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Total Segment Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">434,670</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">226,990</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">661,660</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--CostOfRevenueAbstract_iB_zc6ua3pzTHXc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Cost of Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CostOfRevenue_d0_z2iOY6V0xvOj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Cost of goods sold</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">153,550</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">157,953</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">311,503</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--GrossProfit_d0_zQ5YZAkhjUnl" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Gross Profit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">281,120</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">69,037</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">350,157</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zD7ClbDMlmm5" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Operating Expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--GeneralAndAdministrativeExpense_d0_zBjzZx3mbD85" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">231,318</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">137,141</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,346</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">390,805</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--MarketingAndAdvertisingExpense_d0_zxV8Hbicr1Ed" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Advertising and promotion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,126</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">58,317</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">59,443</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingExpenses_d0_zhqOOaJHpLxc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Segment Operating Expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">232,444</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">195,458</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">22,346</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">450,248</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_d0_z6v9nQVh0tTd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Segment Profit (Loss)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(232,444</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">85,662</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">46,691</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(100,091</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company chooses to disclose the following in its segment reporting requirements for the six months ended June 30, 2025:</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3" id="xdx_495_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_ziupkKSgD4Uh" style="text-align: center"> </td><td> </td> <td colspan="3" id="xdx_491_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--BioleteMember_zxrdDHBxdlyb" style="text-align: center"> </td><td> </td> <td colspan="3" id="xdx_49B_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--AdiaMedMember_zfUZMy3NGngk" style="text-align: center"> </td><td> </td> <td colspan="3" id="xdx_49F_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--AdiaLabsMember_zaDVq4jFZeD1" style="text-align: center"> </td><td> </td> <td colspan="3" id="xdx_49C_20250101__20250630_zCmNLYNoB2ug" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic">For the six months ended June 30, 2025</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Unallocated</td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Corporate</td><td> </td> <td colspan="3" style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">ADIA</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">ADIA</td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Overhead</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Biolete</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Med</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Labs</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Totals</td></tr> <tr id="xdx_408_eus-gaap--SegmentReportingInformationRevenueAbstract_iB_ztJojlaMfVWc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Segment Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--Revenues_d0_hsrt--ProductOrServiceAxis__custom--MedicalProceduresMember_zXoDUWR8Po07" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 30%; text-align: left">Medical procedures</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">96,700</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">96,700</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--Revenues_d0_hsrt--ProductOrServiceAxis__custom--SalesOfBiologicsNetOfDiscountsAndRefundsMember_zZ334ambXLZg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Sales of biologics, net of discounts and refunds</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">87,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">87,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--Revenues_d0_hsrt--ProductOrServiceAxis__custom--SalesOfSupplementsMember_zcgeXYCNPL8l" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Sales of supplements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,155</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,155</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_d0_hsrt--ProductOrServiceAxis__us-gaap--ServiceMember_zE3MfJVqQu2h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Services</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,267</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,288</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,555</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_zsKhdzYmw6uk" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Total Segment Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,267</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,155</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">96,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">88,788</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">189,910</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--CostOfRevenueAbstract_iB_znf04yenfz9e" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Cost of Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--CostOfRevenue_d0_zh1qQuDfkpnh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Cost of goods sold</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">663</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">70,788</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">78,484</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">149,935</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--GrossProfit_zsc7KNmdNbFi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Gross Profit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,267</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,492</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">25,912</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,304</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">39,975</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_z1iN12xXlXid" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Operating Expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_zfNBnbxyssPj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">146,094</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">368</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">89,151</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">307</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">235,920</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--MarketingAndAdvertisingExpense_zCYm2SvVlmLa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Advertising and promotion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">24,617</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">67</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,484</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">17</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">31,185</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingExpenses_ziLh0eETTYkh" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Segment Operating Expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">170,711</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">435</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">95,635</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">324</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">267,105</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingIncomeLoss_z1nBAy1zBEIa" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Segment Profit (Loss)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(168,444</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,057</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(69,723</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,980</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(227,130</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8AC_zhj8QZDoHiz9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_zA1s5dhH6u9a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details - Segment assets)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B5_zMUnxF0UrUr6" style="display: none">Schedule of segment of assets</span></td><td> </td> <td colspan="3" id="xdx_494_20260630_zjQNHwmjPsYa" style="text-align: center"> </td><td> </td> <td colspan="3" id="xdx_49C_20251231_zXEIjF9bBkVk" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2026</b></p></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2025</td></tr> <tr id="xdx_40E_eus-gaap--Assets_iI_d0_hsrt--ProductOrServiceAxis__custom--AdiaMedAssetsMember_zSYyEE8DRjsg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left">Adia Med assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">284,709</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">261,208</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--Assets_iI_d0_hsrt--ProductOrServiceAxis__custom--AdiaLabsAssetsMember_z8Dnd0sTY8zl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Adia Labs assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">305,625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,025</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--Assets_iI_d0_hsrt--ProductOrServiceAxis__custom--UnallocatedCorporateAssetsMember_z7sSjdf2vePl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Unallocated corporate assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">153,720</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">308,593</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Assets_iI_d0_zLb2kYKumu8c" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">744,054</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">594,826</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 284709 261208 305625 25025 153720 308593 744054 594826 <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zo3W6v5EC8Ej" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details - Segment reporting)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B4_zXkg9QgWjz67" style="display: none">Schedule of segment reporting</span></td><td> </td> <td colspan="3" id="xdx_499_20260101__20260630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zmOAw8RsBmT" style="text-align: center"> </td><td> </td> <td colspan="3" id="xdx_49B_20260101__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--BioleteMember_ziJkSeZrOBU8" style="text-align: center"> </td><td> </td> <td colspan="3" id="xdx_493_20260101__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--AdiaMedMember_z0fYqv9U5LG5" style="text-align: center"> </td><td> </td> <td colspan="3" id="xdx_498_20260101__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--AdiaLabsMember_zXLKdK1mykB4" style="text-align: center"> </td><td> </td> <td colspan="3" id="xdx_494_20260101__20260630_zECXRIfKAg37" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic">For the six months ended June 30, 2026</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Unallocated</td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Corporate</td><td> </td> <td colspan="3" style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">ADIA</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">ADIA</td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Overhead</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Biolete</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Med</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Labs</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Totals</td></tr> <tr id="xdx_40D_eus-gaap--SegmentReportingInformationRevenueAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Segment Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_d0_hsrt--ProductOrServiceAxis__custom--MedicalProceduresMember_zdnHoW4XXyp3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 30%; text-align: left">Medical procedures</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">434,670</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">434,670</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--Revenues_d0_hsrt--ProductOrServiceAxis__custom--SalesOfBiologicsNetOfDiscountsAndRefundsMember_zI0zZgXcOk0i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Sales of biologics, net of discounts and refunds</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">221,525</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">221,525</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--Revenues_d0_hsrt--ProductOrServiceAxis__custom--ShippingAndDeliveryMember_z3a82x3uzCb2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Shipping and delivery</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,465</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,465</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--Revenues_d0_zg6Ubsdj4cvb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Total Segment Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">434,670</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">226,990</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">661,660</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--CostOfRevenueAbstract_iB_zc6ua3pzTHXc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Cost of Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CostOfRevenue_d0_z2iOY6V0xvOj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Cost of goods sold</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">153,550</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">157,953</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">311,503</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--GrossProfit_d0_zQ5YZAkhjUnl" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Gross Profit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">281,120</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">69,037</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">350,157</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zD7ClbDMlmm5" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Operating Expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--GeneralAndAdministrativeExpense_d0_zBjzZx3mbD85" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">231,318</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">137,141</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,346</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">390,805</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--MarketingAndAdvertisingExpense_d0_zxV8Hbicr1Ed" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Advertising and promotion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,126</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">58,317</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">59,443</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingExpenses_d0_zhqOOaJHpLxc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Segment Operating Expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">232,444</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">195,458</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">22,346</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">450,248</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_d0_z6v9nQVh0tTd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Segment Profit (Loss)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(232,444</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">85,662</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">46,691</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(100,091</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company chooses to disclose the following in its segment reporting requirements for the six months ended June 30, 2025:</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3" id="xdx_495_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_ziupkKSgD4Uh" style="text-align: center"> </td><td> </td> <td colspan="3" id="xdx_491_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--BioleteMember_zxrdDHBxdlyb" style="text-align: center"> </td><td> </td> <td colspan="3" id="xdx_49B_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--AdiaMedMember_zfUZMy3NGngk" style="text-align: center"> </td><td> </td> <td colspan="3" id="xdx_49F_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--AdiaLabsMember_zaDVq4jFZeD1" style="text-align: center"> </td><td> </td> <td colspan="3" id="xdx_49C_20250101__20250630_zCmNLYNoB2ug" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic">For the six months ended June 30, 2025</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Unallocated</td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Corporate</td><td> </td> <td colspan="3" style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">ADIA</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">ADIA</td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Overhead</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Biolete</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Med</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Labs</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Totals</td></tr> <tr id="xdx_408_eus-gaap--SegmentReportingInformationRevenueAbstract_iB_ztJojlaMfVWc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Segment Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--Revenues_d0_hsrt--ProductOrServiceAxis__custom--MedicalProceduresMember_zXoDUWR8Po07" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 30%; text-align: left">Medical procedures</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">96,700</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">96,700</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--Revenues_d0_hsrt--ProductOrServiceAxis__custom--SalesOfBiologicsNetOfDiscountsAndRefundsMember_zZ334ambXLZg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Sales of biologics, net of discounts and refunds</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">87,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">87,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--Revenues_d0_hsrt--ProductOrServiceAxis__custom--SalesOfSupplementsMember_zcgeXYCNPL8l" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Sales of supplements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,155</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,155</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_d0_hsrt--ProductOrServiceAxis__us-gaap--ServiceMember_zE3MfJVqQu2h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Services</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,267</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,288</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,555</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_zsKhdzYmw6uk" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Total Segment Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,267</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,155</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">96,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">88,788</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">189,910</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--CostOfRevenueAbstract_iB_znf04yenfz9e" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Cost of Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--CostOfRevenue_d0_zh1qQuDfkpnh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Cost of goods sold</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">663</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">70,788</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">78,484</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">149,935</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--GrossProfit_zsc7KNmdNbFi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Gross Profit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,267</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,492</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">25,912</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,304</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">39,975</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_z1iN12xXlXid" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Operating Expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_zfNBnbxyssPj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">146,094</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">368</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">89,151</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">307</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">235,920</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--MarketingAndAdvertisingExpense_zCYm2SvVlmLa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Advertising and promotion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">24,617</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">67</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,484</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">17</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">31,185</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingExpenses_ziLh0eETTYkh" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Segment Operating Expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">170,711</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">435</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">95,635</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">324</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">267,105</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingIncomeLoss_z1nBAy1zBEIa" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Segment Profit (Loss)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(168,444</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,057</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(69,723</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,980</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(227,130</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 0 0 434670 0 434670 0 0 0 221525 221525 0 0 0 5465 5465 0 0 434670 226990 661660 0 0 153550 157953 311503 0 0 281120 69037 350157 231318 0 137141 22346 390805 1126 0 58317 0 59443 232444 0 195458 22346 450248 -232444 0 85662 46691 -100091 0 0 96700 0 96700 0 0 0 87500 87500 0 2155 0 0 2155 2267 0 0 1288 3555 2267 2155 96700 88788 189910 0 663 70788 78484 149935 2267 1492 25912 10304 39975 146094 368 89151 307 235920 24617 67 6484 17 31185 170711 435 95635 324 267105 -168444 1057 -69723 9980 -227130 <p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zSdQGqh4OTYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 14 – <span id="xdx_824_zQxOvCGkRnQl">COMMITMENTS AND CONTINGENCIES</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 5, 2025, the Company retired <span id="xdx_903_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_c20250504__20250505__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember_zR348ya4xh5e" title="Retired shares">15,495,165</span> shares of its Common Stock and declared void <span id="xdx_90B_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_c20250504__20250505__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLFtI0KS8Y0h" title="Retired shares">10,000,000</span> shares of the Company Series A Preferred Shares. Initially, on May 31, 2024, the Company filed a complaint for declaratory relief, seeking an order declaring as void a total of <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_c20240531__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember_zNudtU0GfPa9" title="Shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20240531__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember_zJwDCxsP9cRa" title="Shares outstanding">15,495,165</span></span> shares of the Company’s issued and outstanding shares of Common Stock, held by Lotus Fund (“Lotus”) (<span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20240531__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember__srt--CounterpartyNameAxis__custom--LotusMember_zoqIJm3RKsL7" title="Shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20240531__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember__srt--CounterpartyNameAxis__custom--LotusMember_zmtQu8zBJlSj" title="Shares outstanding">10,495,165</span></span> shares), and Jason S. Coombs (“Coombs”) (<span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_c20240531__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember__srt--CounterpartyNameAxis__custom--CoombsMember_znyF894CZoc3" title="Shares issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20240531__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember__srt--CounterpartyNameAxis__custom--CoombsMember_zfe2xMDTirRc" title="Shares outstanding">5,000,000</span></span> shares). In addition, the lawsuit seeks an order declaring as void a total of 10,000,000 shares of the Company’s issued and outstanding shares of Series A Preferred Shares, held by Shelly Singhal (“Singhal”). Lotus, Coombs and Singhal (collectively the “Claimants”) were issued these shares but the Company deems that they were not properly acquired through any consideration. The lawsuit (Case Number: 2024CA001088, Case Style: ADIA NUTRITION INC -VS- ADIA NUTRITION INC) was filed pursuant to the laws of the State of Florida, and the venue lies in Seminole County. This matter was settled in favor of the Company on May 5, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 15495165 10000000 15495165 15495165 10495165 10495165 5000000 5000000 <p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_zCOkEsPIPmV1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 15 – <span id="xdx_825_zLUsjF6lXsi8">SUBSEQUENT EVENTS</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management has evaluated subsequent events through August 13, 2026, the date these consolidated financial statements were available to be issued. Based on our evaluation, the following material events have occurred that require further disclosure:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2026, the Company issued a total of 2,625,000 shares of the Company’s Preferred C stock . The shares were issued to three directors and the shares due to Cement Factory.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> false false false false